<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41651891</PMID><DateCompleted><Year>2026</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Feb</Month><Day>06</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Bioequivalence assessment between two formulations of a film-coated fixed-dose combination of metformin and vildagliptin&#xa0;(850/50mg) in healthy Tunisian subjects under fed conditions.</ArticleTitle><Pagination><StartPage>5407</StartPage><MedlinePgn>5407</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">5407</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-34082-4</ELocationID><Abstract><AbstractText>In Tunisia, bioequivalence studies have been required for generic drug approval since 2008. This study aimed to assess the bioequivalence of vildagliptin and metformin fixed-dose combination (FDC) 850/50&#xa0;mg for a tested (Bi-Galvine) versus the approved reference products (Galvumet). A randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study with a washout period of 7 days to compare metformin/vildagliptin film-coated tablets in 18 healthy Tunisian subjects aged between 18 and 50 years under fed conditions was conducted at the National Center Chalbi Belkahia of Pharmacovigilance. During each period, 20 blood samples were collected from each subject at pre-dosing (0.00) and between 0.25 and 24.00&#xa0;h after dosing. The bioequivalence between the test (T) and reference (R) products required 90% confidence intervals (CIs) for the geometric least square (LS) mean T/R ratio to be within 80-125% for the pharmacokinetic parameters, maximum plasma concentration (C<sub>max</sub>), and Area Under the Curve from zero to 24&#xa0;h (AUC<sub>0-24&#xa0;h</sub>). The 90% CIs of the geometric means of the T/R ratios for C<sub>max</sub> and AUC<sub>0-24&#xa0;h</sub> for metformin were 92.01-102.66% and 93.55-101.80%, respectively; the corresponding results for vildagliptin were 96.03-107.09% and 94.46-101.92%, respectively. Other parameters, such as AUC<sub>0-&#x221e;</sub>, time to maximum concentration (T<sub>max</sub>), and terminal half-life (t<sub>1/2</sub>), were comparable between the test and reference products. Adverse events (AEs), mainly hypoglycemia and loose stools events, were reported without relevant differences between the test and reference products. AEs were generally mild and transient. No severe or serious AEs occurred. The new generic drug product of metformin/vildagliptin FDC 850/50&#xa0;mg demonstrated bioequivalence to the approved product and is therefore expected to provide similar therapeutic effects.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferchichi</LastName><ForeName>Khouloud</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia. kholod.ferchichi@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia. kholod.ferchichi@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia. kholod.ferchichi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaies</LastName><ForeName>Emna</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Hammamia</LastName><ForeName>Syrine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Jebari</LastName><ForeName>Hanene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daldoul</LastName><ForeName>Mouna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghorbel</LastName><ForeName>Salma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srairi</LastName><ForeName>Semia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guermazi</LastName><ForeName>Sami</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hematology Medical Laboratory at Charles Nicolle Hospital, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorgi</LastName><ForeName>Yousr</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Medical Laboratory at Charles Nicolle Hospital, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutiba</LastName><ForeName>Ilhem</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Microbiology Medical Laboratory at Charles Nicolle Hospital, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouzid</LastName><ForeName>Kahena</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biochemistry Medical Laboratory at Charles Nicolle Hospital, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbessi</LastName><ForeName>Aimen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmacy at Charles Nicolle Hospital, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daghfous</LastName><ForeName>Riadh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Sassi</LastName><ForeName>Mouna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trabelsi</LastName><ForeName>Sameh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, National Center Chalbi Belkahia of Pharmacovigilance, Rue Zouhaier Essafi, 1006, Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Laboratory of Clinical and Experimental Pharmacology (LR16SP02), Tunis, Tunisia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine of Tunis, University of Tunis El Manar, 1007, Tunis, Tunisia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>I6B4B2U96P</RegistryNumber><NameOfSubstance UI="D000077597">Vildagliptin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016568">Drugs, Generic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077597" MajorTopicYN="Y">Vildagliptin</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016568" MajorTopicYN="N">Drugs, Generic</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioavailability</Keyword><Keyword MajorTopicYN="N">Bioequivalence</Keyword><Keyword MajorTopicYN="N">Diabetes</Keyword><Keyword MajorTopicYN="N">Metformin</Keyword><Keyword MajorTopicYN="N">Tunisia</Keyword><Keyword MajorTopicYN="N">Vildagliptin</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>10</Day><Hour>1</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>7</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>6</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41651891</ArticleId><ArticleId IdType="pmc">PMC12886820</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-34082-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-34082-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mbarki, S. <i>et al.</i> EPIDEMIOLOGIE DU DIABETE SUCRE EN TUNISIE.Etude Hammam Sousse Sahloul heart study (HSHS 2). <i>Tunis Med.</i><b>100</b>(3), 229&#x2013;240 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9387647</ArticleId><ArticleId IdType="pubmed">36005915</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymous. Vildagliptin / Metformin Hydrochloride Accord | European Medicines Agency. n.d. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vildagliptin-metformin-hydrochloride-accord [Last accessed: 12/17/2023].</Citation></Reference><Reference><Citation>Anonymous. WMA - The World Medical Association-WMA Declaration of Helsinki &#x2013; Ethical Principles for Medical Research Involving Human Participants. n.d. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki/ [Last accessed: 11/28/2025].</Citation><ArticleIdList><ArticleId IdType="pubmed">39425955</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymous &amp; ICH E6 Good Clinical Practice - Scientific Guideline | European Medicines Agency (EMA). (2002). Available from: https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline [Last accessed: 11/28/2025].</Citation></Reference><Reference><Citation>Anonymous. Investigation of Bioequivalence - Scientific Guideline | European Medicines Agency. n.d. Available from: https://www.ema.europa.eu/en/investigation-bioequivalence-scientific-guideline [Last accessed: 12/17/2023].</Citation></Reference><Reference><Citation>Anonymous Compendium.Ch. n.d. Available from: https://compendium.ch/product/1138799-galvumet-cpr-pell-50-850-mg/mpro [Last accessed: 7/22/2024].</Citation></Reference><Reference><Citation>Research, C. DE and. Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs &#x2014; General Considerations. FDA; (2020). Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioavailability-and-bioequivalence-studies-submitted-ndas-or-inds-general-considerations [Last accessed: 12/17/2023].</Citation></Reference><Reference><Citation>Sen, P. et al. Bioequivalence study of vildagliptin and Metformin fixed dose combinations in healthy volunteers. <i>Indian Practitioner</i>. <b>73</b> (1), 28&#x2013;33 (2020).</Citation></Reference><Reference><Citation>Chow, S-C. &amp; Wang, H. On sample size calculation in bioequivalence trials. <i>J. Pharmacokinet. Pharmacodyn.</i><b>28</b>(2), 155&#x2013;169. 10.1023/A:1011503032353 (2001).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1011503032353</ArticleId><ArticleId IdType="pubmed">11381568</ArticleId></ArticleIdList></Reference><Reference><Citation>Anonymous &amp; ICH M10 on Bioanalytical Method Validation - Scientific Guideline | European Medicines Agency. n.d. Available from: https://www.ema.europa.eu/en/ich-m10-bioanalytical-method-validation-scientific-guideline [Last accessed: 12/17/2023].</Citation></Reference><Reference><Citation>Denney, W., Duvvuri, S. &amp; Buckeridge, C. Simple, automatic noncompartmental analysis: The PKNCA R Package. <i>J. Pharmacokinet. Pharmacodyn.</i><b>42</b>(1), 11&#x2013;107, S65. ISSN 1573&#x2013;8744. 10.1007/s10928-015-9432-2, R package version 0.12.1, (2015). https://github.com/humanpred/pknca</Citation></Reference><Reference><Citation>Bhupathi, C. &amp; Vajjha, V. H. Sample size recommendation for a bioequivalent study. <i>Statistica</i><b>77</b> (1), 65&#x2013;71 (2017).</Citation></Reference><Reference><Citation>Ram&#xed;rez, E. et al. A preliminary model to avoid the overestimation of sample size in bioequivalence studies. <i>Drug Res.</i><b>63</b> (02), 98&#x2013;103. 10.1055/s-0032-1333296 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1333296</ArticleId><ArticleId IdType="pubmed">23427051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye, L. et al. Pharmacokinetics and bioequivalence of a generic Fixed-Dose combination tablet of Metformin Hydrochloride/Vildagliptin versus a branded product in healthy Chinese subjects under fed and fasting conditions. <i>Clin. Pharmacol. Drug Dev.</i><b>11</b> (1), 63&#x2013;70. 10.1002/cpdd.992 (2022).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.992</ArticleId><ArticleId IdType="pubmed">34273258</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, P. et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. <i>J. Clin. Pharmacol.</i><b>49</b> (1), 39&#x2013;49. 10.1177/0091270008325152 (2009).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0091270008325152</ArticleId><ArticleId IdType="pubmed">18832295</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnaars, Y. et al. Bioequivalence studies of new generic formulations of vildagliptin and fixed-drug combination of vildagliptin and Metformin versus respective originator products in healthy volunteers. <i>Diabetes Ther.</i><b>13</b> (6), 1215&#x2013;1229. 10.1007/s13300-022-01269-1 (2022).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13300-022-01269-1</ArticleId><ArticleId IdType="pmc">PMC9174400</ArticleId><ArticleId IdType="pubmed">35543870</ArticleId></ArticleIdList></Reference><Reference><Citation>He, Y-L. et al. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000&#xa0;mg) fixed-dose combination tablet in healthy volunteers. <i>Curr. Med. Res. Opin.</i><b>24</b> (6), 1703&#x2013;1709. 10.1185/03007990802114070 (2008).
</Citation><ArticleIdList><ArticleId IdType="doi">10.1185/03007990802114070</ArticleId><ArticleId IdType="pubmed">18471347</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41634845</PMID><DateRevised><Year>2026</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2661-801X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>BMC chemistry</Title><ISOAbbreviation>BMC Chem</ISOAbbreviation></Journal><ArticleTitle>Green evaluation of human plasma levels of metformin, linagliptin, and empagliflozin using HPLC and HPTLC methods: a pharmacokinetic study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13065-026-01726-z</ELocationID><Abstract><AbstractText>Two simple, rapid, cost-effective, and environmentally friendly chromatographic methods were developed and validated for the simultaneous determination of metformin (MEF), linagliptin (LIN), and empagliflozin (EMP) in human plasma, with successful application to pharmacokinetic study. Plasma sample preparation was performed using a straightforward protein precipitation technique employing acetonitrile: methanol: trichloroacetic acid (50:49:1, by volume), which provided high extraction recovery and minimal matrix interference. The first method was based on high-performance liquid chromatography with diode array detection (HPLC-DAD) using an ODS Hypersil C18 column and isocratic elution with a mobile phase consisting of acetonitrile, methanol, and phosphate buffer (pH 3) in a ratio of (40:40:20, by volume), at a flow rate of 1.3 mL/min, with detection at 230&#xa0;nm. The second method employed high-performance thin-layer chromatography (HPTLC) with densitometric detection at 225&#xa0;nm, using silica gel 60 F254 plates and n-hexane: methanol: glacial acetic acid (6:3:1, by volume) as the developing system. Excellent linearity was achieved over concentration ranges of 85-1650 ng/mL for MEF, 50-1100 ng/mL for EMP, and 45-950 ng/mL for LIN using the HPLC method, and 500-2800, 100-800, and 50-550 ng/band, respectively, using the HPTLC method, with correlation coefficients exceeding 0.998. The lower limits of quantitation for the HPLC method were 85, 50, and 45 ng/mL for MEF, EMP, and LIN, respectively. Both methods demonstrated satisfactory accuracy, precision, recovery (&gt;&#x2009;92%), stability, and negligible matrix effects in accordance with European Medicines Agency guidelines. The validated methods were successfully applied to a pharmacokinetic study in healthy volunteers, yielding mean Cmax values of 877.5&#x2009;&#xb1;&#x2009;162.2 ng/mL (MEF), 576&#x2009;&#xb1;&#x2009;87.5 ng/mL (EMP), and 680.8&#x2009;&#xb1;&#x2009;7.9 ng/mL (LIN), with Tmax values of 2.42&#x2009;&#xb1;&#x2009;0.38, 1.5&#x2009;&#xb1;&#x2009;0.61, and 5.3&#x2009;&#xb1;&#x2009;0.52&#xa0;h, respectively. The obtained pharmacokinetic parameters were consistent with reported literature, confirming the reliability and clinical applicability of the proposed green bioanalytical methods.</AbstractText><CopyrightInformation>&#xa9; 2026. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sattar</LastName><ForeName>Osama I Abdel</ForeName><Initials>OIA</Initials><AffiliationInfo><Affiliation>Pharmaceutical Analytical Chemistry Dept Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 11751, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abuseada</LastName><ForeName>Hamed H M</ForeName><Initials>HHM</Initials><AffiliationInfo><Affiliation>Pharmaceutical Analytical Chemistry Dept Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 11751, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emara</LastName><ForeName>Mohamed Saleh</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Pharmaceutical Analytical Chemistry Dept Faculty of Pharmacy, Al-Azhar University, Nasr City, Cairo, 11751, Egypt. Mohamed.emara83@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selim</LastName><ForeName>Islam</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pharmaceutical Analytical Chemistry Department Faculty of Pharmacy, Badr University in Cairo (BUC), Badr city, Cairo, 8829, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Mohamed A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Faculty of Biotechnology, Badr University in Cairo (BUC), Badr city, Cairo, 8829, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>BMC Chem</MedlineTA><NlmUniqueID>101741142</NlmUniqueID><ISSNLinking>2661-801X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Empagliflozin</Keyword><Keyword MajorTopicYN="N">HPLC</Keyword><Keyword MajorTopicYN="N">Linagliptin</Keyword><Keyword MajorTopicYN="N">Metformin</Keyword><Keyword MajorTopicYN="N">Pharmacokinetic</Keyword><Keyword MajorTopicYN="N">Plasma</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and relevant institutional and national guidelines. The study protocol was reviewed and approved by the Ethics Committee of Badr University in Cairo, Egypt (Approval No. BUC-IACUC/PHA/183/A/2025). Six healthy adult male volunteers aged 18&#x2013;45 years were enrolled in the study. All participants were fully informed about the aims, procedures, and potential risks of the study, and written informed consent was obtained from each participant prior to enrollment. Participant anonymity and data confidentiality were strictly maintained throughout the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>4</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41634845</ArticleId><ArticleId IdType="doi">10.1186/s13065-026-01726-z</ArticleId><ArticleId IdType="pii">10.1186/s13065-026-01726-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Regional office for Europe. WHO European Regional Obesity Report 2022.</Citation></Reference><Reference><Citation>Moradi-Lakeh M, Forouzanfar MH, El Bcheraoui C, Daoud F, Afshin A, Hanson SW, et al. High fasting plasma glucose, diabetes, and its risk factors in the eastern Mediterranean region, 1990&#x2013;2013: findings from the global burden of disease study 2013. Diabetes Care. 2017;40:22&#x2013;9.</Citation></Reference><Reference><Citation>Saeedi P, Salpea P, Karuranga S, Petersohn I, Malanda B, Gregg EW, et al. Mortality attributable to diabetes in 20&#x2013;79 years old adults, 2019 estimates: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2020;162:108086.</Citation></Reference><Reference><Citation>Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420&#x2013;8.</Citation></Reference><Reference><Citation>Kiran T, Parvathi P, Kumar JJ. Development and validation of rp-hplc method for the simultaneous estimation of linagliptin, empagliflozin and metformin in solid dosage forms. Asian J Pharm Anal. 2020;10:117&#x2013;24.</Citation></Reference><Reference><Citation>Shah PA, Shrivastav PS, George AJ. Mixed-mode solid phase extraction combined with LC-MS/MS for determination of empagliflozin and linagliptin in human plasma. Microchem J. 2019;145:523&#x2013;31.</Citation></Reference><Reference><Citation>Neumiller JJ. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitu. Ann Pharmacother. 2012;46:358&#x2013;67.</Citation></Reference><Reference><Citation>Nakka S, Gadthey S, Seema A, Marapakala K. Green assessment of stability indicating RP-HPLC method for simultaneous estimation of metformin, empagliflozin, and linagliptin in bulk and fixed dosage forms using AGREE and GAPI tools. Asian J Green Chem. 2020;8:623&#x2013;41.</Citation></Reference><Reference><Citation>Ganorkar AV, Askarkar SS, Gupta KR, Umekar MJ. Validated stability indicating and assay method development of linagliptin in formulation by RP-HPLC using quality by design. Orbit. 2020;12(2):48&#x2013;61.</Citation></Reference><Reference><Citation>Amin AS, Mohamed SF, Abo-Taleb MM. Stability indicating assay method of metformin, linagliptin and Empagliflozinin pharmaceutical dosage form by HPLC method. Egypt J Chem. 2024;67(7):443&#x2013;9.</Citation></Reference><Reference><Citation>Patel IM, Chhalotiya UK, Jani HD, Kansara D, Kachhiya HM, Shah DA. Simultaneous quantification of empagliflozin, linagliptin and metformin hydrochloride in bulk and synthetic mixture by RP&#x2013;LC method. Future J Pharm Sci. 2021;7:182.</Citation></Reference><Reference><Citation>Yadav CH, Mallibabu A. A RP-LC method in gradient mode for combined quantification of Metformin, Linagliptin, and empagliflozin in combination tablets. J Med Chem Sci. 2022;5:1018&#x2013;25.</Citation></Reference><Reference><Citation>Gurrala S, Raj S, Cvs S, Anumolu PD. Quality-by-design approach for chromatographic analysis of metformin, empagliflozin and linagliptin. J Chromatogr Sci. 2022;60(1):68&#x2013;80.</Citation></Reference><Reference><Citation>Shah D, Meshram D, Patel D, Pradhan P, Patel G. Development and validation of green HPTLC method for simultaneous determination of Dapagliflozin and linagliptin in combined dosage form. Bull Pharm Sci Assiut Univ. 2024;47(2):1037&#x2013;48.</Citation></Reference><Reference><Citation>Patel IM, Chhalotiya UK, Jani HD, Kansara D, Shah DA. Densitometric simultaneous estimation of combination of empagliflozin, linagliptin and Metformin hydrochloride used in the treatment of type 2 diabetes mellitus. JPC-J Planar Chromat. 2020;33:109&#x2013;18.</Citation></Reference><Reference><Citation>Elnadi S, Abdalsabour S, Abdalghany MF, Trabik YA. Stability indicating RP-HPLC and spectrophotometric methods for determination of Gliflozins in their mixture with Metformin. J Iran Chem Soc. 2022;19:1723&#x2013;35.</Citation></Reference><Reference><Citation>Majithia RH, Khodadiya A, Patel VB. Spectrophotometric method development and validation for simultaneous estimation of Anagliptin and Metformin HCl by q - absorption ratio method in synthetic mixture. Heliyon. 2020;6(5):e03855.</Citation></Reference><Reference><Citation>Attimarad M, Nair AB, Nagaraja S, Aldhubiab BE, Venugopala KN, Pottathil SJ. Smart UV derivative spectrophotometric methods for simultaneous determination of Metformin and remogliflozin: development, validation and application to the formulation. Indian J Pharm Educ Res. 2021;55:S293-302.</Citation></Reference><Reference><Citation>Shokouhi S, Sohrabi MR. Net analyte signal and radial basis function neural network for development spectrophotometry method for the simultaneous determination of metformin and sitagliptin in anti-diabetic commercial tablet. Optik. 2021;243:167518.</Citation></Reference><Reference><Citation>Derakhshan MS, Sohrabi MR, Davallo MJ. Developed rapid spectrophotometric method for simultaneous quantitative determination of metformin and linagliptin mixture as antidiabetic drugs by artificial intelligence methodology in biological fluid and pharmaceutical sample. Optik. 2021;241:166922.</Citation></Reference><Reference><Citation>Hassasi S, Hassaninejad-Darzi SK, Vahid AJ. Production of copper-graphene nanocomposite as a voltammetric sensor for determination of anti-diabetic metformin using response surface methodology. Microchem J. 2022;172:106877.</Citation></Reference><Reference><Citation>Haq I, Cruz AG, Di Masi S, Cowen T, Allcock NS, Malitesta C, et al. Smart nano-actuators for electrochemical sensing of Metformin in human plasma. Sens Actuators B Chem. 2023;376:132928.</Citation></Reference><Reference><Citation>D&#x2019;Souza M, Dwivedi P, Lokhande R, Anvekar T, Sharma S, D&#x2019;Souza AJ. A simple sensitive and rapid gas chromatography method for detection and quantization of metformin in metformin tablet formulation, by direct injection, using mass detector. Rasa J Chem. 2022;15(1):334&#x2013;42.</Citation></Reference><Reference><Citation>Emam AA, Habib NM, Mahmoud HM, Abdelwhab NS, Abdelrahman MM. Ecofriendly chromatographic methods for determination of co-prescribed drugs, olanzapine and metformin, in rat plasma. Bioanalysis. 2020;12:597&#x2013;613.</Citation></Reference><Reference><Citation>Magdy MA, Ali NW, Taha AA, Elgebaly AM, Farid NF. Different chromatographic methods for determination of alogliptin benzoate, Metformin hydrochloride, and Metformin impurity in bulk and pharmaceutical dosage form. J Sep Sci. 2021;44:833&#x2013;42.</Citation></Reference><Reference><Citation>Patel IM, Chhalotiya UK, Jani HD, Kansara D, Shah DA. Densitometric simultaneous estimation of combination of empagliflozin, linagliptin and Metformin hydrochloride used in the treatment of type 2 diabetes mellitus. J Planar Chromatogr Mod TLC. 2020;33:109&#x2013;18.</Citation></Reference><Reference><Citation>Alkather Z, Hailat M, Al-Shdefat R, Abu Dayyih WJ. Development and validation of HPLC method for five gliptins in pharmaceutical dosage forms in finished marketed products. Curr Pharm Anal. 2021;17:1263&#x2013;71.</Citation></Reference><Reference><Citation>Vankalapati KR, Alegete P, Boodida SJ. Stability-indicating ultra performance liquid chromatography method development and validation for simultaneous estimation of metformin, linagliptin, and empagliflozin in bulk and pharmaceutical dosage form. Biomed Chromatogr. 2021;35:e5019.</Citation></Reference><Reference><Citation>Abou-Omar M, Kenawy M, Youssef A, Alharthi S, Attia M, Mohamed EH. Validation of a novel UPLC-MS/MS method for estimation of metformin and empagliflozin simultaneously in human plasma using freezing lipid precipitation approach and its application to pharmacokinetic study. J Pharm Biomed Anal. 2021;200:114078.</Citation></Reference><Reference><Citation>European Medicines Agency. Guideline on validation of bioanalytical methods. London: Committee for Medicinal Products for Human Use; 2009.</Citation></Reference><Reference><Citation>Mansour FR, Omer KM, P&#x142;otka-Wasylka J. A total scoring system and software for complex modified GAPI (ComplexMoGAPI) application in the assessment of method greenness. Green Anal Chem. 2024;10:100126.</Citation></Reference><Reference><Citation>Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of Metformin. Clin Pharmacokinet. 2011;50:81&#x2013;98.</Citation></Reference><Reference><Citation>Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle HJ. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clin Ther. 2013;35:A33&#x2013;42.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">41579170</PMID><DateRevised><Year>2026</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1912</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2026</Year><Month>Jan</Month><Day>24</Day></PubDate></JournalIssue><Title>Naunyn-Schmiedeberg's archives of pharmacology</Title><ISOAbbreviation>Naunyn Schmiedebergs Arch Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetic comparison between fixed-dose combination and loose combination of enavogliflozin 0.3 mg and metformin HCl 1000&#xa0;mg in healthy subjects under fasting and fed conditions.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00210-026-04986-7</ELocationID><Abstract><AbstractText>Enavogliflozin is a sodium&#x2012;glucose cotransporter 2 inhibitor that can be administered in combination with metformin in patients with type 2 diabetes mellitus. This study aimed to compare the pharmacokinetics (PKs) between the fixed-dose combination (FDC) and the corresponding loose combination of enavogliflozin 0.3&#xa0;mg and metformin 1000&#xa0;mg. A randomized, open-label, 2-sequence, 4-period crossover study with a single oral dose was conducted in healthy subjects. Subjects received either the FDC or the corresponding loose combination of enavogliflozin 0.3&#xa0;mg and metformin hydrochloride (HCl) 1000&#xa0;mg in fasting and fed states. Serial blood samples were collected up to 72&#xa0;h post-dose. Forty-four subjects were enrolled, and 37 subjects completed the study. In the fasting state, the geometric mean ratios (GMRs) (90% confidential interval (CI)) of the maximum plasma concentration (C<sub>max</sub>) and the area under the concentration-time curve from time zero to the last quantifiable concentration (AUC<sub>last</sub>) of the FDC to those of the corresponding loose combination were 1.03 (0.97-1.10) and 1.08 (1.03-1.13), respectively. The GMRs (90% CI) of the metformin C<sub>max</sub> and AUC<sub>last</sub> of the FDC to those of the corresponding loose combination were 1.10 (1.01-1.19) and 1.05 (1.00-1.11), respectively. In a high-fat-fed state, the GMRs (90% CI) of the enavogliflozin C<sub>max</sub> and AUC<sub>last</sub> of the FDC to those of the corresponding loose combination were 0.88 (0.82-0.93) and 1.03 (0.98-1.09), respectively. The GMRs (90% CI) of the metformin C<sub>max</sub> and AUC<sub>last</sub> of the FDC to those of the corresponding loose combination were 1.01 (0.98-1.05) and 1.00 (0.97-1.04), respectively. All the results were within the conventional bioequivalence range (0.80-1.25). There were no deaths, serious adverse events in fasting high-fat-fed states. The FDC of enavogliflozin 0.3&#xa0;mg and metformin HCl and the corresponding loose combination were pharmacokinetically equivalent without safety concerns in fasting and high-fat-fed states. The FDC can be an alternative option for combination therapy with enavogliflozin and metformin HCl with improved compliance.</AbstractText><CopyrightInformation>&#xa9; 2026. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Surim Meagan</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>CHA University School of Medicine, 120 Hyeryong-Ro, Pocheon-Si, Gyeonggi-Do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Wonsuk</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, CHA University Bundang Medical Center, Seongnam-Si, Gyeonggi-Do, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, CHA University School of Medicine, Seongnam-Si, Gyeonggi-Do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>A-Young</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, CHA University Bundang Medical Center, Seongnam-Si, Gyeonggi-Do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Anhye</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, CHA University Bundang Medical Center, Seongnam-Si, Gyeonggi-Do, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, CHA University School of Medicine, Seongnam-Si, Gyeonggi-Do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yil-Seob</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, CHA University Bundang Medical Center, Seongnam-Si, Gyeonggi-Do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Na</LastName><ForeName>Jaejin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Daewoong Pharmaceutical Co., Ltd., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Jae Min</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Daewoong Pharmaceutical Co., Ltd., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Seoyeon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Daewoong Pharmaceutical Co., Ltd., Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Hyounggyoon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, CHA University Bundang Medical Center, Seongnam-Si, Gyeonggi-Do, Republic of Korea. hgyoo0317@cha.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, CHA University School of Medicine, Seongnam-Si, Gyeonggi-Do, Republic of Korea. hgyoo0317@cha.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>01</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Naunyn Schmiedebergs Arch Pharmacol</MedlineTA><NlmUniqueID>0326264</NlmUniqueID><ISSNLinking>0028-1298</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enavogliflozin</Keyword><Keyword MajorTopicYN="N">Extended-release tablet</Keyword><Keyword MajorTopicYN="N">Fixed-dose combination</Keyword><Keyword MajorTopicYN="N">Metformin</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: Jaejin Na, Jae Min Cho, and Seoyeon Yeon are employees of Daewoong Pharmaceutical. The other authors report no conflicts of interest associated with this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>24</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>24</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>24</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41579170</ArticleId><ArticleId IdType="doi">10.1007/s00210-026-04986-7</ArticleId><ArticleId IdType="pii">10.1007/s00210-026-04986-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>ADA Professional Practice Committee (2025) 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes&#x2014;2025. Diabetes Care 48(Supplement_1):S181-S206</Citation></Reference><Reference><Citation>Bailey CJ et al (2013) Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 11(1):43</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-43</ArticleId><ArticleId IdType="pubmed">23425012</ArticleId><ArticleId IdType="pmc">3606470</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bruin TW et al (2016) Bioequivalence of fixed-dose combinations of dapagliflozin and metformin with single-component tablets in healthy subjects and the effect of food on bioavailability. Clin Pharmacol Drug Dev 5(2):118&#x2013;130</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.220</ArticleId><ArticleId IdType="pubmed">27138025</ArticleId></ArticleIdList></Reference><Reference><Citation>El&#x2010;Damanawi R et al. (2019) Metformin for preventing the progression of chronic kidney disease. Cochrane Database System Rev 2019(9): CD013414</Citation></Reference><Reference><Citation>Graham GG et al (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50(2):81&#x2013;98</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11534750-000000000-00000</ArticleId><ArticleId IdType="pubmed">21241070</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin SJ, Leaver JK, Irving GJ (2017) Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 60(9):1620&#x2013;1629</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4337-9</ArticleId><ArticleId IdType="pubmed">28770324</ArticleId><ArticleId IdType="pmc">5552849</ArticleId></ArticleIdList></Reference><Reference><Citation>Han KA et al (2023) Efficacy and safety of enavogliflozin versus dapagliflozin as add-on to metformin in patients with type 2 diabetes mellitus: a 24-week, double-blind, randomized trial. Diabetes Metab J 47(6):796&#x2013;807</Citation><ArticleIdList><ArticleId IdType="doi">10.4093/dmj.2022.0315</ArticleId><ArticleId IdType="pubmed">36756676</ArticleId><ArticleId IdType="pmc">10695710</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang JG et al (2022) Dose-dependent glucosuria of DWP16001, a novel selective sodium&#x2013;glucose cotransporter-2 inhibitor, in healthy subjects. Br J Clin Pharmacol 88(9):4100&#x2013;4110</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15348</ArticleId><ArticleId IdType="pubmed">35395697</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong SI et al (2023) Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium&#x2013;glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults. Br J Clin Pharmacol 89(6):1780&#x2013;1788</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15632</ArticleId><ArticleId IdType="pubmed">36496349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J-H et al (2020) In vitro metabolism of DWP16001, a novel sodium-glucose cotransporter 2 inhibitor, in human and animal hepatocytes. Pharmaceutics 12(9):865</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics12090865</ArticleId><ArticleId IdType="pubmed">32932946</ArticleId><ArticleId IdType="pmc">7558535</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B et al (2023a) Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium&#x2013;glucose cotransporter 2 inhibitor and metformin in healthy subjects. Br J Clin Pharmacol 89(4):1462&#x2013;1470</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15613</ArticleId><ArticleId IdType="pubmed">36422809</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim M-S et al (2023b) Physiologically based pharmacokinetic modelling to predict pharmacokinetics of enavogliflozin, a sodium-dependent glucose transporter 2 inhibitor, in humans. Pharmaceutics 15(3):942</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15030942</ArticleId><ArticleId IdType="pubmed">36986803</ArticleId><ArticleId IdType="pmc">10058973</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak SH et al (2023) Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 25(7):1865&#x2013;1873</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.15046</ArticleId><ArticleId IdType="pubmed">36872067</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S et al (2025) Evaluation of formulation on the pharmacokinetics, safety, and tolerability of enavogliflozin in healthy Korean adults. Naunyn-Schmiedeberg's Arch Pharmacol 1&#x2013;7</Citation></Reference><Reference><Citation>Marcum ZA, Gellad WF (2012) Medication adherence to multi-drug regimens. Clin Geriatr Med 28(2):287</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cger.2012.01.008</ArticleId><ArticleId IdType="pubmed">22500544</ArticleId><ArticleId IdType="pmc">3335752</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruthur NM et al (2016) Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 164(11):740&#x2013;751</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M15-2650</ArticleId><ArticleId IdType="pubmed">27088241</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauck M et al (2013) Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 15(3):204&#x2013;212</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.12012</ArticleId><ArticleId IdType="pubmed">22985213</ArticleId></ArticleIdList></Reference><Reference><Citation>Preda A et al (2024) SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res 120(5):443&#x2013;460</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvae047</ArticleId><ArticleId IdType="pubmed">38456601</ArticleId><ArticleId IdType="pmc">12001887</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahasrabudhe V et al (2019) Effect of food on the pharmacokinetics of ertugliflozin and its fixed-dose combinations ertugliflozin/sitagliptin and ertugliflozin/metformin. Clin Pharmacol Drug Dev 8(5):619&#x2013;627</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.629</ArticleId><ArticleId IdType="pubmed">30427588</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambol NC et al (1996) Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 36(11):1012&#x2013;1021</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/009127009603601105</ArticleId><ArticleId IdType="pubmed">8973990</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz S et al (2006) Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes available to purchase. Diabetes Care 29(4):759&#x2013;764</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.29.04.06.dc05-1967</ArticleId><ArticleId IdType="pubmed">16567811</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Singh R, Chakraborty PP (2021) Diabetes monotherapies versus metformin-based combination therapy for the treatment of type 2 diabetes. Int J Gen Med. https://doi.org/10.2147/IJGM.S295459</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJGM.S295459</ArticleId><ArticleId IdType="pubmed">34335049</ArticleId><ArticleId IdType="pmc">8318007</ArticleId></ArticleIdList></Reference><Reference><Citation>Solini A, Tric&#xf2; D (2024) Clinical efficacy and cost-effectiveness of metformin in different patient populations: a narrative review of real-world evidence. Diabetes Obes Metab 26:20&#x2013;30</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.15729</ArticleId><ArticleId IdType="pubmed">38939954</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamilselvi M, Srinivas A (2014) Bioequivalence and Pharmacokinetics of Metformin Hydrochloride 1000 mg Tablet extended formulation in healthy Indian male volunteers. J Pharmaceut BioSci 2</Citation></Reference><Reference><Citation>Timmins P et al (2005) Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 44(7):721&#x2013;729</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200544070-00004</ArticleId><ArticleId IdType="pubmed">15966755</ArticleId></ArticleIdList></Reference><Reference><Citation>UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet 352(9131):854&#x2013;865</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41578725</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2160-7648</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical pharmacology in drug development</Title><ISOAbbreviation>Clin Pharmacol Drug Dev</ISOAbbreviation></Journal><ArticleTitle>Bioequivalence Evaluation of Two Metformin/Empagliflozin Fixed-Dose Combination Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions: A Randomized, Open-Label, Crossover Study.</ArticleTitle><Pagination><StartPage>e70029</StartPage><MedlinePgn>e70029</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpdd.70029</ELocationID><Abstract><AbstractText>This study evaluated the bioequivalence and safety of two fixed-dose combination (FDC) tablet formulations of metformin/empagliflozin (1000&#xa0;mg/5&#xa0;mg) in healthy Chinese subjects. A single-center, open-label, randomized, two-period, two-treatment, and two-sequence crossover study was conducted, enrolling 56 subjects who were assigned to either fasting or fed conditions in a 1:1 ratio. Each subject received both the test and reference formulations, with a 7-day washout period between administrations. Blood samples were collected up to 48&#xa0;h post-dose, and plasma concentrations of metformin and empagliflozin were determined using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Bioequivalence was assessed based on key pharmacokinetic parameters-C<sub>max</sub>, AUC<sub>0-t</sub>, and AUC<sub>0-&#x221e;</sub>-with the geometric least-squares mean ratios of the test to reference formulation falling within the accepted bioequivalence range of 80.00% to 125.00% for all 90% confidence intervals under both fasting and fed states. High-fat meals significantly reduced the C<sub>max</sub> of metformin and empagliflozin by approximately 47% and 28%, respectively, and their overall exposure (AUC<sub>0-&#x221e;</sub>) by approximately 29% and 15%, respectively. No serious adverse events were reported. In conclusion, the test and reference formulations of metformin/empagliflozin FDC tablets were bioequivalent and well-tolerated under both fasting and fed conditions.</AbstractText><CopyrightInformation>&#xa9; 2026, The American College of Clinical Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Yuyan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Office of the Drug Clinical Trial Institution, The Second Nanning People's Hospital, Nanning, Guangxi, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xiangya School of Pharmaceutical Science, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yi</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Zhuzhou Central Hospital, Zhuzhou, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Xiangya School of Pharmaceutical Science, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Juli</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Office of the Drug Clinical Trial Institution, The Second Nanning People's Hospital, Nanning, Guangxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Zhenya</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Xiangya School of Pharmaceutical Science, Central South University, Changsha, Hunan, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Jiangsu Feima Pharmaceutical Co., Ltd, Taizhou, Jiangsu, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z-A20231168</GrantID><Agency>Health Commission of Guangxi Zhuang Autonomous Region</Agency><Country/></Grant><Grant><GrantID>2025JJ81185</GrantID><Agency>Hunan Province Natural Science Fund-Medical and Health Union</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Drug Dev</MedlineTA><NlmUniqueID>101572899</NlmUniqueID><ISSNLinking>2160-763X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>HDC1R2M35U</RegistryNumber><NameOfSubstance UI="C570240">empagliflozin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Population" UI="C000724312">Chinese people</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="Y">Glucosides</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005215" MajorTopicYN="N">Fasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001559" MajorTopicYN="Y">Benzhydryl Compounds</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018565" MajorTopicYN="Y">Food-Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N" AutoHM="Y">East Asian People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioequivalence</Keyword><Keyword MajorTopicYN="N">fixed&#x2010;dose combination</Keyword><Keyword MajorTopicYN="N">healthy subjects</Keyword><Keyword MajorTopicYN="N">metformin/empagliflozin</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2026</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>1</Month><Day>24</Day><Hour>3</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41578725</ArticleId><ArticleId IdType="doi">10.1002/cpdd.70029</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Gregg EW, Holman N, Sophiea M, et&#xa0;al., Multiple long&#x2010;term conditions as the next transition in the global diabetes epidemic. Commun Med (Lond). 2025;5(1):42.</Citation></Reference><Reference><Citation>Sun H, Saeedi P, Karuranga S, et&#xa0;al., IDF Diabetes Atlas: Global, regional and country&#x2010;level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.</Citation></Reference><Reference><Citation>Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773&#x2010;795.</Citation></Reference><Reference><Citation>Mahler RJ, Adler ML. Clinical review 102: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab. 1999;84(4):1165&#x2010;1171.</Citation></Reference><Reference><Citation>Davies MJ, Aroda VR, Collins BS, et&#xa0;al., Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753&#x2010;2786.</Citation></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee. 7. Diabetes technology: Standards of Care in Diabetes&#x2010;2024. Diabetes Care. 2024;47(Suppl 1):S126&#x2010;S144.</Citation></Reference><Reference><Citation>Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953&#x2010;966.</Citation></Reference><Reference><Citation>Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577&#x2010;1585.</Citation></Reference><Reference><Citation>Zinman B, Wanner C, Lachin JM, et&#xa0;al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117&#x2010;2128.</Citation></Reference><Reference><Citation>Goldman JD. Combination of empagliflozin and metformin therapy: a consideration of its place in type 2 diabetes therapy. Clin Med Insights Endocrinol Diabetes. 2018;11:1179551418786258.</Citation></Reference><Reference><Citation>Matthews D, Del Prato S, Mohan V, et&#xa0;al., Insights from verify: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther. 2020;11(11):2465&#x2010;2476.</Citation></Reference><Reference><Citation>Matthews DR, Pald&#xe1;nius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5&#x2010;year, multicentre, randomised, double&#x2010;blind trial. Lancet. 2019;394(10208):1519&#x2010;1529.</Citation></Reference><Reference><Citation>B&#xf6;hm AK, Schneider U, Stargardt T. Economic effects of fixed&#x2010;dose versus loose&#x2010;dose combination therapy for type 2 diabetes patients. Appl Health Econ Health Policy. 2023;21(1):109&#x2010;118.</Citation></Reference><Reference><Citation>B&#xf6;hm AK, Schneider U, Aberle J, Stargardt T. Regimen simplification and medication adherence: Fixed&#x2010;dose versus loose&#x2010;dose combination therapy for type 2 diabetes. PLoS One. 2021;16(5):e0250993.</Citation></Reference><Reference><Citation>Rojas C, Link J, Meinicke T, Macha S. Pharmacokinetics of fixed&#x2010;dose combinations of empagliflozin/metformin compared with individual tablets in healthy subjects. Int J Clin Pharmacol Ther. 2016;54(4):282&#x2010;292.</Citation></Reference><Reference><Citation>Rosenstock J, Seman LJ, Jelaska A, et&#xa0;al., Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add&#x2010;on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15(12):1154&#x2010;1160.</Citation></Reference><Reference><Citation>Huang X, Huang J, Li X, Chen L. Pharmacokinetic and bioequivalence studies of 2 metformin glibenclamide tablets in healthy Chinese subjects under fasting and fed conditions. Clin Pharmacol Drug Dev. 2023;12(5):509&#x2010;517.</Citation></Reference><Reference><Citation>Ye L, Li B, Ling N, et&#xa0;al., Pharmacokinetics and bioequivalence of a generic fixed&#x2010;dose combination tablet of metformin hydrochloride/vildagliptin versus a branded product in healthy Chinese subjects under fed and fasting conditions. Clin Pharmacol Drug Dev. 2022;11(1):63&#x2010;70.</Citation></Reference><Reference><Citation>Lei Y, Yan Y, Huang L, et&#xa0;al., Pharmacokinetics and bioequivalence of two combination metformin/glipizide tablets under fasting and fed conditions in Chinese healthy subjects: a randomized, open&#x2010;label, crossover study. J Clin Pharm Ther. 2024;49(5):9200636.</Citation></Reference><Reference><Citation>Sun ML, Liu F, Yan P, Chen W, Wang XH. Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: A meta&#x2010;analysis of pharmacokinetic, bioavailability, or bioequivalence studies. Heliyon. 2023;9(7):e17906.</Citation></Reference><Reference><Citation>Cheng L, Wong H. Food effects on oral drug absorption: application of physiologically&#x2010;based pharmacokinetic modeling as a predictive tool. Pharmaceutics. 2020;12(7):672.</Citation></Reference><Reference><Citation>Reynaud Y, Buffi&#xe8;re C, David J, et&#xa0;al., Temporal changes in postprandial intragastric pH: Comparing measurement methods, food structure effects, and kinetic modelling. Food Res Int. 2020;128:108784.</Citation></Reference><Reference><Citation>Zhu Y, Hsu WH, Hollis JH. The impact of food viscosity on eating rate, subjective appetite, glycemic response and gastric emptying rate. PLoS One. 2013;8(6):e67482.</Citation></Reference><Reference><Citation>Cheng M, Ren L, Jia X, Wang J, Cong B. Understanding the action mechanisms of metformin in the gastrointestinal tract. Front Pharmacol. 2024;15:1347047.</Citation></Reference><Reference><Citation>Olafuyi O, Parekh N, Wright J, Koenig J. Inter&#x2010;ethnic differences in pharmacokinetics&#x2010;is there more that unites than divides? Pharmacol Res Perspect. 2021;9(6):e00890.</Citation></Reference><Reference><Citation>Jang K, Chung H, Yoon J&#x2010;S, et&#xa0;al., Pharmacokinetics, safety, and tolerability of metformin in healthy elderly subjects. J Clin Pharmacol. 2016;56(9):1104&#x2010;1110.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41315088</PMID><DateCompleted><Year>2026</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0428</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>3</Issue><PubDate><Year>2026</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Diabetologia</Title><ISOAbbreviation>Diabetologia</ISOAbbreviation></Journal><ArticleTitle>Ketone supplementation dose-dependently lowers postprandial blood glucose, lipid and ghrelin levels in individuals with type 2 diabetes: a randomised crossover study.</ArticleTitle><Pagination><StartPage>752</StartPage><EndPage>763</EndPage><MedlinePgn>752-763</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00125-025-06614-0</ELocationID><Abstract><AbstractText Label="AIMS/HYPOTHESIS" NlmCategory="OBJECTIVE">Postprandial hyperglycaemia and hyperlipidaemia are independent risk factors for CVD in individuals with type 2 diabetes. We aimed to test whether a ketone monoester (KE) and ketone salts (KS) reduce postprandial glucose and lipid excursions in individuals with type 2 diabetes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In two randomised, participant-blind crossover studies we investigated individuals with type 2 diabetes treated with either metformin monotherapy or a lifestyle intervention alone. In study 1, 14 participants received 30 g of KE, KS or placebo 30 min before a mixed meal test on three separate occasions. The primary outcome was the incremental AUC (iAUC) for glucose. In study 2, ten participants were investigated on six separate occasions, consuming various doses (0 g, 10 g, 20 g and 40 g) of KE 30 min, 60 min or immediately before an OGTT. Both studies were conducted at Aarhus University Hospital, Denmark, with the primary investigator randomly assigning the intervention order.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We found that the iAUC for glucose decreased by 36% (95% CI 14, 57) with KE and 22% (95% CI 1, 44) with KS compared with placebo. Both ketone supplements lowered postprandial NEFA and ghrelin concentrations, and KE reduced triglycerides (n=14). Furthermore, KE dose-dependently lowered the iAUC of glucose, with the strongest effect when ingested 30 min or 60 min before the OGTT (n=10). No serious adverse events occurred; however, transient mild gastrointestinal symptoms, including nausea and diarrhoea, were reported.</AbstractText><AbstractText Label="CONCLUSIONS/INTERPRETATION" NlmCategory="CONCLUSIONS">Pre-meal ketone supplementation reduced postprandial glucose, lipid and ghrelin concentrations. These findings support the therapeutic potential of KE supplementation in the management of type 2 diabetes.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov NCT05263401 and NCT05581043 FUNDING: Novo Nordisk Foundation (NNF19OC0058872 and NNF22OC0081911), the Health Research Foundation of Central Denmark Region and the Aase Einar Danielsen Foundation (Jr. No. 23-10-0145).</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bangshaab</LastName><ForeName>Maj</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6265-2854</Identifier><AffiliationInfo><Affiliation>Medical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bengtsen</LastName><ForeName>Mads B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0001-8985-8385</Identifier><AffiliationInfo><Affiliation>Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smedegaard</LastName><ForeName>Stine</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0225-8809</Identifier><AffiliationInfo><Affiliation>Medical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xf8;ndergaard</LastName><ForeName>Esben</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8041-6994</Identifier><AffiliationInfo><Affiliation>Medical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Niels</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5627-7322</Identifier><AffiliationInfo><Affiliation>Medical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svart</LastName><ForeName>Mads V</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0000-0002-9574-0612</Identifier><AffiliationInfo><Affiliation>Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rittig</LastName><ForeName>Nikolaj</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9938-2181</Identifier><AffiliationInfo><Affiliation>Medical/Steno Aarhus Research Laboratory, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Nikolaj.rittig@clin.au.dk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark. Nikolaj.rittig@clin.au.dk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. Nikolaj.rittig@clin.au.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05263401</AccessionNumber><AccessionNumber>NCT05581043</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>NNF19OC0058872</GrantID><Agency>Novo Nordisk Fonden</Agency><Country/></Grant><Grant><GrantID>NNF22OC0081911</GrantID><Agency>Novo Nordisk Fonden</Agency><Country/></Grant><Grant><GrantID>Jr. No. 23-10-0145</GrantID><Agency>Aase og Ejnar Danielsens Fond</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Diabetologia</MedlineTA><NlmUniqueID>0006777</NlmUniqueID><ISSNLinking>0012-186X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007659">Ketones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054439">Ghrelin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="Y">Blood Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019518" MajorTopicYN="N">Postprandial Period</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007659" MajorTopicYN="Y">Ketones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054439" MajorTopicYN="Y">Ghrelin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="Y">Lipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="N">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ketones</Keyword><Keyword MajorTopicYN="N">Metabolism</Keyword><Keyword MajorTopicYN="N">Postprandial hyperglycaemia</Keyword><Keyword MajorTopicYN="N">Postprandial hyperlipidaemia</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword><Keyword MajorTopicYN="N">&#x3b2;-Hydroxybutyrate</Keyword></KeywordList><CoiStatement>Acknowledgements: The authors would like to express their sincere gratitude to all study participants for their generous contributions of time and effort. We are deeply thankful to L. Buus, E. Hornemann, M. L. Schwartz, S. Birk Wittorff, L. Mentz and E. Schriver (Medical/Steno Aarhus Research Laboratory, Aarhus University) for their skilled technical expertise and invaluable assistance during the studies. The authors take full responsibility for the content and all statements presented in the manuscript. Data availability: The data supporting this study will be made available on reasonable request. Funding: The study was supported by the Novo Nordisk Foundation (NNF19OC0058872 and NNF22OC0081911), the Health Research Foundation of Central Denmark Region and the Aase Einar Danielsen Fund (Jr. No. 23-10-0145). Authors&#x2019; relationships and activities: NM is the co-founder of Mmimetika Biosciences ApS, a spin-out company entitled to develop and sell a newly invented lactate/ketone body ester. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. Contribution statement: MB, MBB, NM, SS, MVS and NR conceived and designed the studies. MB, MBB and SS conducted the studies. MB and MBB analysed the data. MB, MBB, NM, ES, MVS and NR contributed to the interpretation of results. MB and MBB drafted the manuscript. MB, MBB, NM, SS, ES, MVS and NR reviewed and approved the final manuscript. NR, MVS, MB and MBB are the guarantors, accept full responsibility for the work, have access to the data and control the decision to publish.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>6</Day><Hour>14</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>29</Day><Hour>2</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>28</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41315088</ArticleId><ArticleId IdType="doi">10.1007/s00125-025-06614-0</ArticleId><ArticleId IdType="pii">10.1007/s00125-025-06614-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ceriello A (2005) Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54(1):1&#x2013;7. https://doi.org/10.2337/diabetes.54.1.1</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.54.1.1</ArticleId><ArticleId IdType="pubmed">15616004</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K, Miyoshi T, Yunoki K, Ito H (2016) Postprandial hyperlipidemia as a potential residual risk factor. J Cardiol 67(4):335&#x2013;339. https://doi.org/10.1016/j.jjcc.2015.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jjcc.2015.12.001</ArticleId><ArticleId IdType="pubmed">26744235</ArticleId></ArticleIdList></Reference><Reference><Citation>Traugott K (1922) &#xfc;ber das Verhalten des Blutzuckerspiegels bei Wiederholter und Verschiedener Art Enteraler Zuckerzufuhr und Dessen Bedeutung f&#xfc;r die Leberfunktion. Klinische Wochenschrift 1(18):892&#x2013;894 [article in German]. https://doi.org/10.1007/BF01715866</Citation></Reference><Reference><Citation>Smedegaard S, Kampmann U, Ovesen PG, St&#xf8;vring H, Rittig N (2023) Whey protein premeal lowers postprandial glucose concentrations in adults compared with water-the effect of timing, dose, and metabolic status: a systematic review and meta-analysis. Am J Clin Nutr 118(2):391&#x2013;405. https://doi.org/10.1016/j.ajcnut.2023.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajcnut.2023.05.012</ArticleId><ArticleId IdType="pubmed">37536867</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteyne AJ, Falkenhain K, Whelehan G et al (2024) A ketone monoester drink reduces postprandial blood glucose concentrations in adults with type 2 diabetes: a randomised controlled trial. Diabetologia 67(6):1107&#x2013;1113. https://doi.org/10.1007/s00125-024-06122-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-024-06122-7</ArticleId><ArticleId IdType="pubmed">38483543</ArticleId><ArticleId IdType="pmc">11058041</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalasingam N, Berg-Hansen K, Christensen KH et al (2024) Randomized crossover trial of 2-week ketone ester treatment in patients with type 2 diabetes and heart failure with preserved ejection fraction. Circulation 150(20):1570&#x2013;1583. https://doi.org/10.1161/circulationaha.124.069732</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.124.069732</ArticleId><ArticleId IdType="pubmed">39162035</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg-Hansen K, Gopalasingam N, Christensen KH et al (2024) Cardiovascular effects of oral ketone ester treatment in patients with heart failure with reduced ejection fraction: a randomized, controlled, double-blind trial. Circulation 149(19):1474&#x2013;1489. https://doi.org/10.1161/circulationaha.123.067971</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.123.067971</ArticleId><ArticleId IdType="pubmed">38533643</ArticleId><ArticleId IdType="pmc">11081479</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen NJ, Nilsson M, Ingerslev JS et al (2020) Effects of &#x3b2;-hydroxybutyrate on cognition in patients with type 2 diabetes. Eur J Endocrinol 182(2):233&#x2013;242. https://doi.org/10.1530/eje-19-0710</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/eje-19-0710</ArticleId><ArticleId IdType="pubmed">31821157</ArticleId></ArticleIdList></Reference><Reference><Citation>Svart M, Rittig N, Pedersen SB, Jessen N, M&#xf8;ller N (2020) Oral 3-hydroxybutyrate ingestion decreases endogenous glucose production, lipolysis, and hormone-sensitive lipase phosphorylation in adipose tissue in men: a human randomized, controlled, crossover trial. Diabet Med 38(2):e14385. https://doi.org/10.1111/dme.14385</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dme.14385</ArticleId><ArticleId IdType="pubmed">32794582</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubbs BJ, Cox PJ, Evans RD et al (2017) On the metabolism of exogenous ketones in humans. Front Physiol 8:848. https://doi.org/10.3389/fphys.2017.00848</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2017.00848</ArticleId><ArticleId IdType="pubmed">29163194</ArticleId><ArticleId IdType="pmc">5670148</ArticleId></ArticleIdList></Reference><Reference><Citation>Puchalska P, Crawford PA (2017) Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab 25(2):262&#x2013;284. https://doi.org/10.1016/j.cmet.2016.12.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2016.12.022</ArticleId><ArticleId IdType="pubmed">28178565</ArticleId><ArticleId IdType="pmc">5313038</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf8;ller N (2020) Ketone body, 3-hydroxybutyrate: minor metabolite - major medical manifestations. J Clin Endocrinol Metab 105(9):2884&#x2013;2892. https://doi.org/10.1210/clinem/dgaa370</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa370</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela PL, Castillo-Garc&#xed;a A, Morales JS, Lucia A (2021) Perspective: ketone supplementation in sports-does it work? Adv Nutr 12(2):305&#x2013;315. https://doi.org/10.1093/advances/nmaa130</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/advances/nmaa130</ArticleId><ArticleId IdType="pubmed">33094332</ArticleId><ArticleId IdType="pmc">8243601</ArticleId></ArticleIdList></Reference><Reference><Citation>Falkenhain K, Daraei A, Forbes SC, Little JP (2022) Effects of exogenous ketone supplementation on blood glucose: a systematic review and meta-analysis. Adv Nutr 13(5):1697&#x2013;1714. https://doi.org/10.1093/advances/nmac036</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/advances/nmac036</ArticleId><ArticleId IdType="pubmed">35380602</ArticleId><ArticleId IdType="pmc">9526861</ArticleId></ArticleIdList></Reference><Reference><Citation>Duca FA, Waise TMZ, Peppler WT, Lam TKT (2021) The metabolic impact of small intestinal nutrient sensing. Nat Commun 12(1):903. https://doi.org/10.1038/s41467-021-21235-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21235-y</ArticleId><ArticleId IdType="pubmed">33568676</ArticleId><ArticleId IdType="pmc">7876101</ArticleId></ArticleIdList></Reference><Reference><Citation>Rittig N, Svart M, Thomsen HH et al (2020) Oral D/L-3-hydroxybutyrate stimulates cholecystokinin- and insulin secretion and slows gastric emptying in healthy males. J Clin Endocrinol Metab 105(10):dgaa483. https://doi.org/10.1210/clinem/dgaa483</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa483</ArticleId><ArticleId IdType="pubmed">32717058</ArticleId></ArticleIdList></Reference><Reference><Citation>Taggart AK, Kero J, Gan X et al (2005) (D)-&#x3b2;-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem 280(29):26649&#x2013;26652. https://doi.org/10.1074/jbc.C500213200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C500213200</ArticleId><ArticleId IdType="pubmed">15929991</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikkelsen KH, Seifert T, Secher NH, Gr&#xf8;ndal T, van Hall G (2015) Systemic, cerebral and skeletal muscle ketone body and energy metabolism during acute hyper-D-&#x3b2;-hydroxybutyratemia in post-absorptive healthy males. J Clin Endocrinol Metab 100(2):636&#x2013;643. https://doi.org/10.1210/jc.2014-2608</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2014-2608</ArticleId><ArticleId IdType="pubmed">25415176</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubbs BJ, Cox PJ, Evans RD, Cyranka M, Clarke K, de Wet H (2018) A ketone ester drink lowers human ghrelin and appetite. Obesity (Silver Spring) 26(2):269&#x2013;273. https://doi.org/10.1002/oby.22051</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.22051</ArticleId><ArticleId IdType="pubmed">29105987</ArticleId></ArticleIdList></Reference><Reference><Citation>Vestergaard ET, Zubanovic NB, Rittig N et al (2021) Acute ketosis inhibits appetite and decreases plasma concentrations of acyl ghrelin in healthy young men. Diabetes Obes Metab 23(8):1834&#x2013;1842. https://doi.org/10.1111/dom.14402</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14402</ArticleId><ArticleId IdType="pubmed">33852195</ArticleId></ArticleIdList></Reference><Reference><Citation>Myette-C&#xf4;t&#xe9; &#xc9;, Neudorf H, Rafiei H, Clarke K, Little JP (2018) Prior ingestion of exogenous ketone monoester attenuates the glycaemic response to an oral glucose tolerance test in healthy young individuals. J Physiol 596(8):1385&#x2013;1395. https://doi.org/10.1113/jp275709</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jp275709</ArticleId><ArticleId IdType="pubmed">29446830</ArticleId><ArticleId IdType="pmc">5899975</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagata T, Tamura Y, Kaga H et al (2021) Ingestion of an exogenous ketone monoester improves the glycemic response during oral glucose tolerance test in individuals with impaired glucose tolerance: a cross-over randomized trial. J Diabetes Investig 12(5):756&#x2013;762. https://doi.org/10.1111/jdi.13423</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.13423</ArticleId><ArticleId IdType="pubmed">33010116</ArticleId></ArticleIdList></Reference><Reference><Citation>Melenovsk&#xfd; V, Ho&#x161;kov&#xe1; E, Velebov&#xe1; K et al (2024) Metformin improves glycemic control and postprandial metabolism and enhances postprandial glucagon-like peptide 1 secretion in patients with type 2 diabetes and heart failure: a randomized, double-blind, placebo-controlled trial. Clini Diabetes 43(1):23&#x2013;32. https://doi.org/10.2337/cd24-0003</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/cd24-0003</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie C, Iroga P, Bound MJ et al (2024) Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study. Diabetologia 67(7):1260&#x2013;1270. https://doi.org/10.1007/s00125-024-06131-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-024-06131-6</ArticleId><ArticleId IdType="pubmed">38561463</ArticleId><ArticleId IdType="pmc">11153273</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333(9):541&#x2013;549. https://doi.org/10.1056/nejm199508313330902</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199508313330902</ArticleId><ArticleId IdType="pubmed">7623902</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschner P, Kipnes MS, Lunceford JK et al (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29(12):2632&#x2013;2637. https://doi.org/10.2337/dc06-0703</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc06-0703</ArticleId><ArticleId IdType="pubmed">17130196</ArticleId></ArticleIdList></Reference><Reference><Citation>Falkenhain K, Oliveira BF, Islam H et al (2024) The effect of acute and 14-day exogenous ketone supplementation on glycemic control in adults with type 2 diabetes: two randomized controlled trials. Am J Physiol Endocrinol Metab 326(1):E61&#x2013;E72. https://doi.org/10.1152/ajpendo.00332.2023</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpendo.00332.2023</ArticleId><ArticleId IdType="pubmed">37991451</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Q, Falkenhain K, Little JP et al (2023) Effects of ketone supplements on blood &#x3b2;-hydroxybutyrate, glucose and insulin: a systematic review and three-level meta-analysis. Complement Ther Clin Pract 52:101774. https://doi.org/10.1016/j.ctcp.2023.101774</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctcp.2023.101774</ArticleId><ArticleId IdType="pubmed">37327753</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolhurst G, Reimann F, Gribble FM (2009) Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 587(1):27&#x2013;32. https://doi.org/10.1113/jphysiol.2008.164012</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2008.164012</ArticleId><ArticleId IdType="pubmed">19001044</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#x2019;Kadmi C, Cabral A, Barrile F et al (2019) N-terminal liver-expressed antimicrobial peptide 2 (LEAP2) region exhibits inverse agonist activity toward the ghrelin receptor. J Med Chem 62(2):965&#x2013;973. https://doi.org/10.1021/acs.jmedchem.8b01644</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.8b01644</ArticleId><ArticleId IdType="pubmed">30543423</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagemann CA, Jensen MS, Holm S et al (2022) LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men. Cell Rep Med 3(4):100582. https://doi.org/10.1016/j.xcrm.2022.100582</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100582</ArticleId><ArticleId IdType="pubmed">35492241</ArticleId><ArticleId IdType="pmc">9043997</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm SK, Vestergaard ET, Zubanovic NB et al (2023) Ketone monoester increases circulating levels of LEAP2 and decreases appetite in healthy men. Diabetes Obes Metab 25(7):2023&#x2013;2027. https://doi.org/10.1111/dom.15044</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.15044</ArticleId><ArticleId IdType="pubmed">36867127</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen MGB, Lauritzen ES, Svart MV et al (2023) Nutrient sensing: LEAP2 concentration in response to fasting, glucose, lactate, and &#x3b2;-hydroxybutyrate in healthy young males. Am J Clin Nutr 118(6):1091&#x2013;1098. https://doi.org/10.1016/j.ajcnut.2023.10.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajcnut.2023.10.007</ArticleId><ArticleId IdType="pubmed">37844838</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke K, Tchabanenko K, Pawlosky R et al (2012) Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol 63(3):401&#x2013;408. https://doi.org/10.1016/j.yrtph.2012.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yrtph.2012.04.008</ArticleId><ArticleId IdType="pubmed">22561291</ArticleId><ArticleId IdType="pmc">3810007</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivva V, Cox PJ, Clarke K, Veech RL, Tucker IG, Duffull SB (2016) The population pharmacokinetics of d-&#x3b2;-hydroxybutyrate following administration of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate. AAPS J 18(3):678&#x2013;688. https://doi.org/10.1208/s12248-016-9879-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-016-9879-0</ArticleId><ArticleId IdType="pubmed">26893218</ArticleId><ArticleId IdType="pmc">5256599</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotson CD, Zhang L, Xu H et al (2008) Bitter taste receptors influence glucose homeostasis. PLoS One 3(12):e3974. https://doi.org/10.1371/journal.pone.0003974</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003974</ArticleId><ArticleId IdType="pubmed">19092995</ArticleId><ArticleId IdType="pmc">2597743</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41261763</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1942-7611</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Drug testing and analysis</Title><ISOAbbreviation>Drug Test Anal</ISOAbbreviation></Journal><ArticleTitle>Metformin in the Horse: Pharmacokinetics and Detection Times Using Monte Carlo Simulations.</ArticleTitle><Pagination><StartPage>139</StartPage><EndPage>148</EndPage><MedlinePgn>139-148</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/dta.70000</ELocationID><Abstract><AbstractText>The racehorse industry has strict regulations regarding the detection of prohibited substances in horses. Metformin, a diabetes medication, is a prohibited substance that has been reported in post-race blood and urine samples collected from racehorses. For further characterization of the disposition of metformin, 12 Thoroughbred horses were administered metformin orally and intravenously in a randomized, balanced, two-way crossover design. Serum and urine samples were collected, and drug concentrations determined via liquid chromatography-tandem mass spectrometry. The serum data were analyzed using both noncompartmental analysis and a population pharmacokinetic model. Metformin concentrations were below the LOQ (0.25&#x2009;ng/mL) in six of 12 horses by Day 11 postadministration, and below the LOQ for all horses on Day 25. The maximum serum concentration of metformin (mean&#x2009;&#xb1;&#x2009;SD) was 941.0&#x2009;&#xb1;&#x2009;467.8&#x2009;ng/mL, and the mean terminal t<sub>1/2</sub> was 85.8&#x2009;&#xb1;&#x2009;15.1&#x2009;h. Based on Monte Carlo simulations the time that serum metformin concentrations fell below the proposed HISA Anti-Doping and Medication Control (ADMC) minimum reporting level (MRL; 0.5&#x2009;ng/mL) in a simulated population of 1000 Thoroughbred horses was 475&#x2009;hrs (~20 days). Metformin concentrations in urine fluctuated significantly between and within individual horses, and there was not a consistent relationship between blood and urine samples across time points. Results of the present study demonstrate a prolonged detection time; thus, a prolonged withdrawal time is needed to prevent a positive finding following exposure to metformin. Additionally, these results suggest that blood is the preferred matrix for regulatory purposes due to the inconsistent elimination in urine.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Drug Testing and Analysis published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Megan E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>K.L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blea</LastName><ForeName>Jeff</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Veterinary Medicine, University of California, Davis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Racing Medication and Testing Consortium, Lexington, Kentucky, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKemie</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>K.L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traynham</LastName><ForeName>Megan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>K.L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knych</LastName><ForeName>Heather K</ForeName><Initials>HK</Initials><Identifier Source="ORCID">0000-0002-8676-4970</Identifier><AffiliationInfo><Affiliation>K.L. Maddy Equine Analytical Chemistry Laboratory (Pharmacology Section), School of Veterinary Medicine, University of California, Davis, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Racing Medication and Testing Consortium</Agency><Country/></Grant><Grant><Agency>Horseracing Integrity and Safety Authority</Agency><Country/></Grant><Grant><Agency>Horseracing Integrity &amp; Welfare Unit</Agency><Country/></Grant><Grant><Agency>California Horse Racing Board</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Drug Test Anal</MedlineTA><NlmUniqueID>101483449</NlmUniqueID><ISSNLinking>1942-7603</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006736" MajorTopicYN="N">Horses</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009010" MajorTopicYN="N">Monte Carlo Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015813" MajorTopicYN="Y">Substance Abuse Detection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000662" MajorTopicYN="N">veterinary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004300" MajorTopicYN="N">Doping in Sports</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>13</Day><Hour>7</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>20</Day><Hour>1</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41261763</ArticleId><ArticleId IdType="pmc">PMC12796554</ArticleId><ArticleId IdType="doi">10.1002/dta.70000</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bailey C. J. and Turner R. C., &#x201c;Metformin,&#x201d; New England Journal of Medicine 334, no. 9 (1996): 574&#x2013;579, 10.1056/NEJM199602293340906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199602293340906</ArticleId><ArticleId IdType="pubmed">8569826</ArticleId></ArticleIdList></Reference><Reference><Citation>Rena G., Hardie D. G., and Pearson E. R., &#x201c;The Mechanisms of Action of Metformin,&#x201d; Diabetologia 60, no. 9 (2017): 1577&#x2013;1585, 10.1007/s00125-017-4342-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4342-z</ArticleId><ArticleId IdType="pmc">PMC5552828</ArticleId><ArticleId IdType="pubmed">28776086</ArticleId></ArticleIdList></Reference><Reference><Citation>McCreight L. J., Bailey C. J., and Pearson E. R., &#x201c;Metformin and the Gastrointestinal Tract,&#x201d; Diabetologia 59, no. 3 (2016): 426&#x2013;435, 10.1007/s00125-015-3844-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-015-3844-9</ArticleId><ArticleId IdType="pmc">PMC4742508</ArticleId><ArticleId IdType="pubmed">26780750</ArticleId></ArticleIdList></Reference><Reference><Citation>Tinworth K. D., Boston R. C., Harris P. A., Sillence M. N., Raidal S. L., and Noble G. K., &#x201c;The Effect of Oral Metformin on Insulin Sensitivity in Insulin&#x2010;Resistant Ponies,&#x201d; Veterinary Journal 191, no. 1 (2012): 79&#x2013;84, 10.1016/j.tvjl.2011.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tvjl.2011.01.015</ArticleId><ArticleId IdType="pubmed">21349749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hustace J. L., Firshman A. M., and Mata J. E., &#x201c;Pharmacokinetics and Bioavailability of Metformin in Horses,&#x201d; American Journal of Veterinary Research 70, no. 5 (2009): 665&#x2013;668, 10.2460/ajvr.70.5.665.</Citation><ArticleIdList><ArticleId IdType="doi">10.2460/ajvr.70.5.665</ArticleId><ArticleId IdType="pubmed">19405907</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S., Behera S. K., Srinivasan A., et&#xa0;al., &#x201c;Effect of Metformin on Exercise Capacity: A Meta&#x2010;Analysis,&#x201d; Diabetes Research and Clinical Practice 144 (2018): 270&#x2013;278, 10.1016/j.diabres.2018.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2018.08.022</ArticleId><ArticleId IdType="pubmed">30217594</ArticleId></ArticleIdList></Reference><Reference><Citation>Knych H. K., Arthur R. M., Mitchell M. M., et&#xa0;al., &#x201c;Pharmacokinetics and Selected Pharmacodynamics of Cobalt Following a Single Intravenous Administration to Horses,&#x201d; Drug Testing and Analysis 7, no. 7 (2015): 619&#x2013;625, 10.1002/dta.1737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dta.1737</ArticleId><ArticleId IdType="pubmed">25327415</ArticleId></ArticleIdList></Reference><Reference><Citation>
Fda, Cder
&#x201c;Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Bioanalytical Method Validation Guidance for Industry Biopharmaceutics Contains Nonbinding Recommendations&#x201d; (2018) https://www.fda.gov/files/drugs/published/Bioanalytical&#x2010;Method&#x2010;Validation&#x2010;Guidance&#x2010;for&#x2010;Industry.pdf.</Citation></Reference><Reference><Citation>Bon C., Toutain P. L., Concordet D., et&#xa0;al., &#x201c;Mathematical Modeling and Simulation in Animal Health. Part III: Using Nonlinear Mixed&#x2010;Effects to Characterize and Quantify Variability in Drug Pharmacokinetics,&#x201d; Journal of Veterinary Pharmacology and Therapeutics 41, no. 2 (2018): 171&#x2013;183, 10.1111/jvp.12473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jvp.12473</ArticleId><ArticleId IdType="pubmed">29226975</ArticleId></ArticleIdList></Reference><Reference><Citation>Toutain P. L., &#x201c;Why the Racing Industry and Equestrian Disciplines Need to Implement Population Pharmacokinetics: To Learn, Explain, Summarize, Harmonize, and Individualize,&#x201d; Drug Testing and Analysis 17, no. 2 (2025): 250&#x2013;258, 10.1002/dta.3706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dta.3706</ArticleId><ArticleId IdType="pmc">PMC11842173</ArticleId><ArticleId IdType="pubmed">38685692</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S., Jeon S., and Han S., &#x201c;Population Pharmacokinetic Analysis of Metformin Administered as Fixed&#x2010;Dose Combination in Korean Healthy Adults,&#x201d; Translational and Clinical Pharmacology 26, no. 1 (2018): 25&#x2013;31, 10.12793/tcp.2018.26.1.25.</Citation><ArticleIdList><ArticleId IdType="doi">10.12793/tcp.2018.26.1.25</ArticleId><ArticleId IdType="pmc">PMC6989222</ArticleId><ArticleId IdType="pubmed">32055544</ArticleId></ArticleIdList></Reference><Reference><Citation>Pentik&#xe4;inen P. J., Neuvonen P. J., and Penttil&#xe4; A., &#x201c;Pharmacokinetics of Metformin After Intravenous and Oral Administration to Man,&#x201d; European Journal of Clinical Pharmacology 16, no. 3 (1979): 195&#x2013;202, 10.1007/BF00562061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00562061</ArticleId><ArticleId IdType="pubmed">499320</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker G. T., Casey C., Phillips P. J., Connor H., Ward J. D., and Woods H. F., &#x201c;Metformin Kinetics in Healthy Subjects and in Patients With Diabetes Mellitus,&#x201d; British Journal of Clinical Pharmacology 12, no. 2 (1981): 235&#x2013;246, 10.1111/j.1365-2125.1981.tb01206.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1981.tb01206.x</ArticleId><ArticleId IdType="pmc">PMC1401849</ArticleId><ArticleId IdType="pubmed">7306436</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert F., Fendri S., Hary L., Lacroix C., Andr&#xe9;jak M., and Lalau J. D., &#x201c;Kinetics of Plasma and Erythrocyte Metformin After Acute Administration in Healthy Subjects,&#x201d; Diabetes &amp; Metabolism 29, no. 3 (2003): 279&#x2013;283, 10.1016/s1262-3636(07)70037-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1262-3636(07)70037-x</ArticleId><ArticleId IdType="pubmed">12909816</ArticleId></ArticleIdList></Reference><Reference><Citation>Masereeuw R. and Russel F. G., &#x201c;Mechanisms and Clinical Implications of Renal Drug Excretion,&#x201d; Drug Metabolism Reviews 33, no. 3&#x2013;4 (2001): 299&#x2013;351, 10.1081/dmr-120000654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1081/dmr-120000654</ArticleId><ArticleId IdType="pubmed">11768771</ArticleId></ArticleIdList></Reference><Reference><Citation>Toutain P. L., &#x201c;How to Extrapolate a Withdrawal Time From an EHSLC Published Detection Time: A Monte Carlo Simulation Appraisal,&#x201d; Equine Veterinary Journal 42, no. 3 (2010): 248&#x2013;254, 10.1111/j.2042-3306.2010.00028.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2042-3306.2010.00028.x</ArticleId><ArticleId IdType="pubmed">20486982</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroda T., Minamijima Y., Nomura M., et&#xa0;al., &#x201c;Medication Control of Flunixin in Racing Horses: Possible Detection Times Using Monte Carlo Simulations,&#x201d; Equine Veterinary Journal 54, no. 5 (2022): 979&#x2013;988, 10.1111/evj.13532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/evj.13532</ArticleId><ArticleId IdType="pmc">PMC9546317</ArticleId><ArticleId IdType="pubmed">34719043</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheurer M., Michel A., Brauch H. J., Ruck W., and Sacher F., &#x201c;Occurrence and Fate of the Antidiabetic Drug Metformin and Its Metabolite Guanylurea in the Environment and During Drinking Water Treatment,&#x201d; Water Research 46, no. 15 (2012): 4790&#x2013;4802, 10.1016/j.watres.2012.06.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.watres.2012.06.019</ArticleId><ArticleId IdType="pubmed">22770965</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41206775</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-5762</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Drug development and industrial pharmacy</Title><ISOAbbreviation>Drug Dev Ind Pharm</ISOAbbreviation></Journal><ArticleTitle>Bioequivalence and pharmacokinetic prediction of oral marketed metformin extended-release tablets in Saudi Arabia.</ArticleTitle><Pagination><StartPage>153</StartPage><EndPage>162</EndPage><MedlinePgn>153-162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/03639045.2025.2586793</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The Saudi market offers dosages of metformin that have varying release rates and can lead to different pharmacological reactions. Studying formulation bioequivalences helps patients choose the optimum medicine without affecting pharmacological responses.</AbstractText><AbstractText Label="SIGNIFICANCE" NlmCategory="UNASSIGNED">This study affects patient care clinically, which can improve Saudi diabetes management by improving efficacy, safety, adherence, access, and cultural relevance.</AbstractText><AbstractText Label="METHOD" NlmCategory="UNASSIGNED">The bioequivalence and pharmacokinetic parameters were studied using the convolution method. Similarity factor f<sub>1</sub> and different factors f<sub>2</sub> of different types of metformin tablets were calculated. Furthermore, the pharmacokinetic parameters were estimated using the convolution method.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">At pH = 6.8 (phosphate buffer) and 50&#x2009;rpm, 100% of metformin was released within 2&#x2009;h. While, after two hours in HCl at pH = 1.1 followed by five hours in phosphate buffer at pH = 6.8, 100% of the medication was released after 7&#x2009;h. The release kinetics showed zero-order kinetics with r<sup>2</sup> = 0.961 for Formit<sup>&#xae;</sup> and 0.971 for Glucophage<sup>&#xae;</sup>, while the release mechanism showed that it follows the Higuchi equation with r<sup>2</sup> = 0.974 for Formit<sup>&#xae;</sup> and 0.971 for Glucophage<sup>&#xae;</sup>, respectively, indicating that the mechanism of drug release was controlled by diffusion. The two brands were lyo-equivalent, with a similarity factor and difference factor equal to 59.36 and 7.26, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The convolution approach indicated that Glucophage<sup>&#xae;</sup> and Formit<sup>&#xae;</sup> have bioequivalent C<sub>max</sub> of 601 and 592&#x2009;ng/ml, respectively. The two products had the same projected T<sub>max</sub> of 2.0&#x2009;h and a modest AUC<sub>&#x221e;</sub> differential that did not violate the FDA's 80-125% limit.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alrashidi</LastName><ForeName>Talal S</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraidah, Kingdom of Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amin</LastName><ForeName>Mohammed A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraidah, Kingdom of Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aljutyali</LastName><ForeName>Abdullah S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraidah, Kingdom of Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alwadi</LastName><ForeName>Aiman Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, Alfaisal University, Riyadh, Kingdom of Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ameer</LastName><ForeName>Omar Z</ForeName><Initials>OZ</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, College of Pharmacy, Alfaisal University, Riyadh, Kingdom of Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Mohamed A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, College of Pharmacy, King Saud University, Kingdom of Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdellatif</LastName><ForeName>Ahmed A H</ForeName><Initials>AAH</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraidah, Kingdom of Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alomary</LastName><ForeName>Abdulaziz Abdulrrahman</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraidah, Kingdom of Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maswadeh</LastName><ForeName>Hamzah M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraidah, Kingdom of Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>11</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Drug Dev Ind Pharm</MedlineTA><NlmUniqueID>7802620</NlmUniqueID><ISSNLinking>0363-9045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012529" MajorTopicYN="N" Type="Geographic">Saudi Arabia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Metformin</Keyword><Keyword MajorTopicYN="N">bioequivalence</Keyword><Keyword MajorTopicYN="N">comparative analysis</Keyword><Keyword MajorTopicYN="N">k release</Keyword><Keyword MajorTopicYN="N">quality control</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>6</Day><Hour>19</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>9</Day><Hour>14</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41206775</ArticleId><ArticleId IdType="doi">10.1080/03639045.2025.2586793</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">41155987</PMID><DateCompleted><Year>2025</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Oct</Month><Day>20</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Virtual Bioequivalence Assessment and Dissolution Safe Space Exploration for Fixed-Dose Metformin-Glyburide Tablet Using Physiologically Based Biopharmaceutics Modeling.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1352</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics17101352</ELocationID><Abstract><AbstractText><b>Background/Objectives</b>: Fixed-dose combinations (FDCs) hold significant clinical value for the management of hypertension, diabetes and other chronic diseases. However, since the complexity of formulations, generic compounds require both in vitro pharmaceutical equivalence and in vivo bioequivalence (BE) for each active pharmaceutical ingredient (API). Physiologically based biopharmaceutics modeling (PBBM) not only bridges in vitro drug properties to in vivo pharmacokinetics but effectively assesses the impact of formulations on systemic exposure. This study was aimed at developing a PBBM for metformin-glyburide FDC and investigating its clinically relevant quality specifications. <b>Methods</b>: PK-Sim<sup>&#xae;</sup> software (Version 11.3) was used to establish a PBBM for a metformin-glyburide FDC. Sensitivity analysis identified critical parameters and guided design of virtual populations. Subsequently, virtual bioequivalence (VBE) was assessed between both reference and test formulations, and BE-ensuring dissolution space was explored by the change in dissolution characteristics. <b>Results</b>: The in vivo behavior of products was successfully captured by the developed model. Sensitivity analysis indicated that systemic exposure was primarily sensitive to gastrointestinal (GI) pH and transit times. VBE analysis confirmed BE between the reference and test formulations. The dissolution safe space for the FDC was defined as the concurrent achievement of &#x2265; 50% dissolution within 25 min for metformin and between 35 and 170 min for glyburide, which constituted equivalent specification. <b>Conclusions</b>: The PBBM developed in this study systematically evaluated the VBE of metformin-glyburide FDC, optimized the acceptance criteria for traditional in vitro dissolution testing, and thereby explored its clinically relevant quality specification.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Chenshuang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu 610064, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Chaozhuang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu 610064, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yumeng</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu 610064, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ling</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3220-6065</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu 610064, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>B18035</GrantID><Agency>Ling Wang</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PK-Sim</Keyword><Keyword MajorTopicYN="N">fixed-dose combination (FDC)</Keyword><Keyword MajorTopicYN="N">glyburide</Keyword><Keyword MajorTopicYN="N">metformin</Keyword><Keyword MajorTopicYN="N">physiologically based biopharmaceutics modeling (PBBM)</Keyword><Keyword MajorTopicYN="N">safe space</Keyword><Keyword MajorTopicYN="N">sensitivity analysis</Keyword><Keyword MajorTopicYN="N">virtual bioequivalence (VBE)</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>10</Month><Day>29</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41155987</ArticleId><ArticleId IdType="pmc">PMC12566952</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics17101352</ArticleId><ArticleId IdType="pii">pharmaceutics17101352</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>U.S. Food and Drug Administration (FDA)   Hypertension: Developing Fixed-Combination Drug Products for Treatment. Center for Drug Evaluation and Research (CDER); Silver Spring, MD, USA: 2018.  [(accessed on 28 September 2025)].  Guidance for Industry. Available online:  https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.</Citation></Reference><Reference><Citation>Fillinger L., Walter S., Ley M., K&#x119;ska-Izworska K., Dehkordi L.G., Kratochwill K., Perco P. Computational Modeling Approaches and Regulatory Pathways for Drug Combinations. Drug Discov. Today. 2025;30:104345. doi: 10.1016/j.drudis.2025.104345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2025.104345</ArticleId><ArticleId IdType="pubmed">40158836</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen S., Ganta B., Rachel V.N., Gogikar S.K., Singh V., Sonti R., Dikundwar A.G. Mapping Advantages and Challenges in Analytical Development for Fixed Dose Combination Products, a Review. J. Pharm. Sci. 2024;113:2028&#x2013;2043. doi: 10.1016/j.xphs.2024.04.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2024.04.025</ArticleId><ArticleId IdType="pubmed">38697403</ArticleId></ArticleIdList></Reference><Reference><Citation>IDF Diabetes Atlas. 2025.  [(accessed on 28 September 2025)].  Available online:  https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/</Citation></Reference><Reference><Citation>The American Diabetes Association Releases the Standards of Care in Diabetes&#x2014;2024.  [(accessed on 28 September 2025)].  Available online:  https://diabetes.org/newsroom/press-releases/american-diabetes-association-releases-standards-care-diabetes-2024.</Citation></Reference><Reference><Citation>NICE  Type 2 Diabetes in Adults: Management.  [(accessed on 28 September 2025)].  Available online:  https://www.nice.org.uk/guidance/ng28.</Citation></Reference><Reference><Citation>Shuster D.L., Shireman L.M., Ma X., Shen D.D., Flood Nichols S.K., Ahmed M.S., Clark S., Caritis S., Venkataramanan R., Haas D.M., et al. Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus. Clin. Pharmacol. Ther. 2020;107:1362&#x2013;1372. doi: 10.1002/cpt.1749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1749</ArticleId><ArticleId IdType="pmc">PMC7561209</ArticleId><ArticleId IdType="pubmed">31869430</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., Huang J., Li X., Chen L. Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Clin. Pharmacol. Drug Dev. 2023;12:509&#x2013;517. doi: 10.1002/cpdd.1219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.1219</ArticleId><ArticleId IdType="pubmed">36642944</ArticleId></ArticleIdList></Reference><Reference><Citation>International Council for Harmonisation . ICH M13A: Bioequivalence for Immediate-Release Solid Oral Dosage Forms. ICH; Geneva, Switzerland: 2023.</Citation></Reference><Reference><Citation>European Medicines Agency . Guideline on Clinical Development of Fixed Combination Medicinal Products. European Medicines Agency (EMA); Amsterdam, The Netherlands: 2017.</Citation></Reference><Reference><Citation>Center for Drug Evaluation . Technical Guideline for Bioavailability and Bioequivalence Studies of Chemical Drug Products. National Medical Products Administration (NMPA); Beijing, China: 2005.</Citation></Reference><Reference><Citation>Bhattiprolu A.K., Kollipara S., Boddu R., Arumugam A., Khan S.M., Ahmed T. A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation. Aaps Pharmscitech. 2024;25:193. doi: 10.1208/s12249-024-02904-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-024-02904-9</ArticleId><ArticleId IdType="pubmed">39168956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanke N., T&#xfc;rk D., Selzer D., Ishiguro N., Ebner T., Wiebe S., M&#xfc;ller F., Stopfer P., Nock V., Lehr T. A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug&#x2013;Drug&#x2013;Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals. Clin. Pharmacokinet. 2020;59:1419&#x2013;1431. doi: 10.1007/s40262-020-00896-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-020-00896-w</ArticleId><ArticleId IdType="pmc">PMC7658088</ArticleId><ArticleId IdType="pubmed">32449077</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Zhang Z., Li P., Kong W., Liu X., Liu L. A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators. Pharmaceutics. 2021;13:698. doi: 10.3390/pharmaceutics13050698.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13050698</ArticleId><ArticleId IdType="pmc">PMC8151202</ArticleId><ArticleId IdType="pubmed">34064886</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Guo H., Liu C., Zhong Z., Liu L., Liu X. Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model. Clin. Pharmacokinet. 2015;54:179&#x2013;193. doi: 10.1007/s40262-014-0192-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-014-0192-8</ArticleId><ArticleId IdType="pubmed">25316573</ArticleId></ArticleIdList></Reference><Reference><Citation>Klumpp L., Dressman J. Physiologically Based Pharmacokinetic Model Outputs Depend on Dissolution Data and Their Input: Case Examples Glibenclamide and Dipyridamole. Eur. J. Pharm. Sci. 2020;151:105380. doi: 10.1016/j.ejps.2020.105380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2020.105380</ArticleId><ArticleId IdType="pubmed">32442630</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration . The Use of Physiologically Based Pharmacokinetic Analyses&#x2014;Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls: Guidance for Industry (Draft) U.S. Food and Drug Administration (U.S. FDA); Silver Spring, MD, USA: 2020.</Citation></Reference><Reference><Citation>Derbalah A., Abdulla T., De Sousa Mendes M., Wu Q., Stader F., Jamei M., Gardner I., Sepp A. Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial. Pharmaceutics. 2025;17:604. doi: 10.3390/pharmaceutics17050604.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics17050604</ArticleId><ArticleId IdType="pmc">PMC12115112</ArticleId><ArticleId IdType="pubmed">40430895</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackie C., Arora S., Seo P., Moody R., Rege B., Pepin X., Heimbach T., Tannergren C., Mitra A., Suarez-Sharp S., et al. Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report. Mol. Pharm. 2024;21:2065&#x2013;2080. doi: 10.1021/acs.molpharmaceut.4c00202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.4c00202</ArticleId><ArticleId IdType="pmc">PMC11080464</ArticleId><ArticleId IdType="pubmed">38600804</ArticleId></ArticleIdList></Reference><Reference><Citation>Arora S., Pepin X., Jamei M., Sharma P., Heimbach T., Wagner C., Bransford P., Kollipara S., Ahmed T., Hingle M., et al. Development of a Physiologically Based Biopharmaceutics Model Report Template: Considerations for Improved Quality in View of Regulatory Submissions. Mol. Pharm. 2025;22:2735&#x2013;2746. doi: 10.1021/acs.molpharmaceut.5c00225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.5c00225</ArticleId><ArticleId IdType="pmc">PMC12135060</ArticleId><ArticleId IdType="pubmed">40300064</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuepfer L., Niederalt C., Wendl T., Schlender J.-F., Willmann S., Lippert J., Block M., Eissing T., Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT Pharmacomet. Syst. Pharmacol. 2016;5:516&#x2013;531. doi: 10.1002/psp4.12134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.12134</ArticleId><ArticleId IdType="pmc">PMC5080648</ArticleId><ArticleId IdType="pubmed">27653238</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham G.G., Punt J., Arora M., Day R.O., Doogue M.P., Duong J.K., Furlong T.J., Greenfield J.R., Greenup L.C., Kirkpatrick C.M., et al. Clinical Pharmacokinetics of Metformin. Clin. Pharmacokinet. 2011;50:81&#x2013;98. doi: 10.2165/11534750-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11534750-000000000-00000</ArticleId><ArticleId IdType="pubmed">21241070</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai D., Wong B., Huang Y., Ye Q., Tang D., Guo H., Huang M., Timmins P. Surfactant-Mediated Dissolution of Metformin Hydrochloride Tablets: Wetting Effects versus Ion Pairs Diffusivity. J. Pharm. Sci. 2014;103:920&#x2013;926. doi: 10.1002/jps.23852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.23852</ArticleId><ArticleId IdType="pubmed">24549733</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M., Xia L., Wang J. Metformin Transport by a Newly Cloned Proton-Stimulated Organic Cation Transporter (Plasma Membrane Monoamine Transporter) Expressed in Human Intestine. Drug Metab. Dispos. 2007;35:1956&#x2013;1962. doi: 10.1124/dmd.107.015495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.107.015495</ArticleId><ArticleId IdType="pmc">PMC2672958</ArticleId><ArticleId IdType="pubmed">17600084</ArticleId></ArticleIdList></Reference><Reference><Citation>Greupink R., Schreurs M., Benne M.S., Huisman M.T., Russel F.G.M. Semi-Mechanistic Physiologically-Based Pharmacokinetic Modeling of Clinical Glibenclamide Pharmacokinetics and Drug&#x2013;Drug-Interactions. Eur. J. Pharm. Sci. 2013;49:819&#x2013;828. doi: 10.1016/j.ejps.2013.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2013.06.009</ArticleId><ArticleId IdType="pubmed">23806476</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirasaka Y., Seki M., Hatakeyama M., Kurokawa Y., Uchiyama H., Takemura M., Yasugi Y., Kishimoto H., Tamai I., Wang J., et al. Multiple Transport Mechanisms Involved in the Intestinal Absorption of Metformin: Impact on the Nonlinear Absorption Kinetics. J. Pharm. Sci. 2022;111:1531&#x2013;1541. doi: 10.1016/j.xphs.2022.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2022.01.008</ArticleId><ArticleId IdType="pubmed">35090865</ArticleId></ArticleIdList></Reference><Reference><Citation>Bristol-Myers Squibb Company . GLUCOVANCE&#xae; (Glyburide and Metformin Hydrochloride) Tablets: Highlights of Prescribing Information. Bristol-Myers Squibb Company; New York, NY, USA: 2000. Initial U.S. Approval.</Citation></Reference><Reference><Citation>Proks P., Kramer H., Haythorne E., Ashcroft F.M. Binding of Sulphonylureas to Plasma Proteins&#x2014;A KATP Channel Perspective. PLoS ONE. 2018;13:e0197634. doi: 10.1371/journal.pone.0197634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0197634</ArticleId><ArticleId IdType="pmc">PMC5957440</ArticleId><ArticleId IdType="pubmed">29772022</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Huo M., Zhou J., Zou A., Li W., Yao C., Xie S. DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles. AAPS J. 2010;12:263&#x2013;271. doi: 10.1208/s12248-010-9185-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-010-9185-1</ArticleId><ArticleId IdType="pmc">PMC2895453</ArticleId><ArticleId IdType="pubmed">20373062</ArticleId></ArticleIdList></Reference><Reference><Citation>Najjar A., Hamadeh A., Krause S., Schepky A., Edginton A. Global Sensitivity Analysis of Open Systems Pharmacology Suite Physiologically Based Pharmacokinetic Models. CPT Pharmacomet. Syst. Pharmacol. 2024;13:2052&#x2013;2067. doi: 10.1002/psp4.13256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/psp4.13256</ArticleId><ArticleId IdType="pmc">PMC11646943</ArticleId><ArticleId IdType="pubmed">39498820</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency  Guideline on the Reporting of Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulation. EMA/CHMP/458101/2016. 2018.  [(accessed on 28 January 2021)].  Available online:  https://www.ema.europa.eu/en/Documents/Scientific-Guideline/Guideline-Reporting-Physiologically-Based-Pharmacokinetic-Pbpk-Modelling-Simulation_en.pdf.</Citation></Reference><Reference><Citation>Niemi M., Backman J.T., Neuvonen M., Neuvonen P.J., Kivist&#xf6; K.T. Effects of Rifampin on the Pharmacokinetics and Pharmacodynamics of Glyburide and Glipizide. Clin. Pharmacol. Ther. 2001;69:400&#x2013;406. doi: 10.1067/mcp.2001.115822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mcp.2001.115822</ArticleId><ArticleId IdType="pubmed">11406737</ArticleId></ArticleIdList></Reference><Reference><Citation>Lilja J.J., Niemi M., Fredrikson H., Neuvonen P.J. Effects of Clarithromycin and Grapefruit Juice on the Pharmacokinetics of Glibenclamide. Br. J. Clin. Pharmacol. 2007;63:732&#x2013;740. doi: 10.1111/j.1365-2125.2006.02836.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2006.02836.x</ArticleId><ArticleId IdType="pmc">PMC2000598</ArticleId><ArticleId IdType="pubmed">17223855</ArticleId></ArticleIdList></Reference><Reference><Citation>Varma M.V.S., Scialis R.J., Lin J., Bi Y.-A., Rotter C.J., Goosen T.C., Yang X. Mechanism-Based Pharmacokinetic Modeling to Evaluate Transporter-Enzyme Interplay in Drug Interactions and Pharmacogenetics of Glyburide. AAPS J. 2014;16:736&#x2013;748. doi: 10.1208/s12248-014-9614-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-014-9614-7</ArticleId><ArticleId IdType="pmc">PMC4070267</ArticleId><ArticleId IdType="pubmed">24839071</ArticleId></ArticleIdList></Reference><Reference><Citation>Donahue S.R., Turner K.C., Patel S. Pharmacokinetics and Pharmacodynamics of Glyburide/Metformin Tablets (GlucovanceTM) Versus Equivalent Doses of Glyburide and Metformin in Patients with Type 2 Diabetes. Clin. Pharmacokinet. 2002;41:1301&#x2013;1309. doi: 10.2165/00003088-200241150-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200241150-00004</ArticleId><ArticleId IdType="pubmed">12452739</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnqvist H.J., Karlberg B.E., Melander A. Pharmacokinetics and Effects of Glibenclamide in Two Formulations, HB 419 and HB 420, in Type 2 Diabetes. Ann. Clin. Res. 1983;15((Suppl. S37)):21&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">6433769</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai D., Wang J., Wen H., Li X., Timmins P. Formulation Design, Challenges, and Development Considerations for Fixed Dose Combination (FDC) of Oral Solid Dosage Forms. Pharm. Dev. Technol. 2013;18:1265&#x2013;1276. doi: 10.3109/10837450.2012.660699.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10837450.2012.660699</ArticleId><ArticleId IdType="pubmed">22339230</ArticleId></ArticleIdList></Reference><Reference><Citation>Belayneh A., Molla F., Kahsay G. Formulation and Optimization of Monolithic Fixed-Dose Combination of Metformin HCl and Glibenclamide Orodispersible Tablets. Adv. Pharm. Pharm. Sci. 2020;2020:3546597. doi: 10.1155/2020/3546597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/3546597</ArticleId><ArticleId IdType="pmc">PMC7094173</ArticleId><ArticleId IdType="pubmed">32259103</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattiprolu A.K., Kollipara S., Boddu R., Ahmed T. Justification of Widened Dissolution Specifications of an Extended-Release Product Using Physiologically Based Biopharmaceutics Modeling. Xenobiotica. 2024;54:781&#x2013;795. doi: 10.1080/00498254.2024.2411980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00498254.2024.2411980</ArticleId><ArticleId IdType="pubmed">39361244</ArticleId></ArticleIdList></Reference><Reference><Citation>Tannergren C., Arora S., Babiskin A., Borges L., Chatterjee P., Cheng Y.-H., Dallmann A., Govada A., Heimbach T., Hingle M., et al. Current State and New Horizons in Applications of Physiologically Based Biopharmaceutics Modeling (PBBM): A Workshop Report. Mol. Pharm. 2025;22:5&#x2013;27. doi: 10.1021/acs.molpharmaceut.4c01148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.4c01148</ArticleId><ArticleId IdType="pmc">PMC11707736</ArticleId><ArticleId IdType="pubmed">39680866</ArticleId></ArticleIdList></Reference><Reference><Citation>Loisios-Konstantinidis I., Cristofoletti R., Fotaki N., Turner D.B., Dressman J. Establishing Virtual Bioequivalence and Clinically Relevant Specifications Using in Vitro Biorelevant Dissolution Testing and Physiologically-Based Population Pharmacokinetic Modeling. Case Example. Eur. J. Pharm. Sci. 2020;143:105170. doi: 10.1016/j.ejps.2019.105170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2019.105170</ArticleId><ArticleId IdType="pubmed">31783158</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolph N., Charbe N., Plano D., Shoyaib A.A., Pal A., Boyce H., Zhao L., Wu F., Polli J., Dressman J., et al. A Physiologically Based Biopharmaceutics Modeling (PBBM) Framework for Characterizing Formulation-Dependent Food Effects: Paving the Road towards Fed State Virtual BE Studies for Itraconazole Amorphous Solid Dispersions. Eur. J. Pharm. Sci. 2025;209:107047. doi: 10.1016/j.ejps.2025.107047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2025.107047</ArticleId><ArticleId IdType="pubmed">39983931</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Alvarez I., Ruiz-Picazo A., Selles-Talavera R., Figueroa-Campos A., Merino V., Bermejo M., Gonzalez-Alvarez M. In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug. Pharmaceutics. 2024;16:390. doi: 10.3390/pharmaceutics16030390.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics16030390</ArticleId><ArticleId IdType="pmc">PMC10974868</ArticleId><ArticleId IdType="pubmed">38543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Guideline for the Testing and Comparison of Dissolution Curves of Ordinary Oral Solid Preparations.  [(accessed on 28 September 2025)];2016  Available online:  https://www.nmpa.gov.cn/directory/web/nmpa/zhuanti/ypqxgg/ggzhcfg/20160318210001633.html.</Citation></Reference><Reference><Citation>Therapeutic Goods Administration  ICH M9 Guideline on Biopharmaceutics Classification System-Based Biowaivers. 2024.  [(accessed on 28 September 2025)].  Available online:  https://www.ema.europa.eu/en/ich-m9-biopharmaceutics-classification-system-based-biowaivers-scientific-guideline.</Citation></Reference><Reference><Citation>Abuhelwa A.Y., Williams D.B., Upton R.N., Foster D.J.R. Food, gastrointestinal pH, and models of oral drug absorption. Eur. J. Pharm. Biopharm. 2017;112:234&#x2013;248. doi: 10.1016/j.ejpb.2016.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2016.11.034</ArticleId><ArticleId IdType="pubmed">27914234</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40951699</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1177-8881</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Drug design, development and therapy</Title><ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetic and Pharmacodynamic Interaction of Metformin and Ojeok-san in Healthy Volunteers.</ArticleTitle><Pagination><StartPage>7825</StartPage><EndPage>7836</EndPage><MedlinePgn>7825-7836</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S526915</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">This study aimed to evaluate the pharmacokinetics and pharmacodynamics of metformin and Ojeok-san (OJS) co-administration to healthy volunteers compared to those with metformin alone.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This was an open-label, one-sequence, crossover study, with two 2-day hospitalization schedules lasting up to 14 days. Metformin was administered once daily on days 1 and 2. OJS was administered alone three times a day on days 3-7 and co-administered with metformin once a day on days 8 and 9. Plasma concentrations of metformin were measured using a validated LC-MS/MS method. To evaluate pharmacodynamics, oral glucose tolerance tests (OGTTs) were performed on days 1, 2, 8 and 9.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Fifteen participants were enrolled. The coadministration decreased C<sub>max</sub> (1757.7 to 1668.9 ng/mL) and AUC<sub>last</sub> (10407.4 to 9901.1 ng&#xb7;h/mL), compared to those with metformin alone. Geometric mean ratios (90% Confidence Interval) of C<sub>max</sub> and AUC<sub>last</sub> between the co-administration with OJS and metformin alone were 92.15% (82.79-102.57) and 94.57% (85.6-104.48), respectively. Co-administration with OJS did not significantly change the mean glucose level compared to that with metformin alone.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Co-administration with OJS decreased the plasma concentrations of metformin compared to that with metformin alone. However, the degree of decrease was not significant based on the geometric mean of the C<sub>max</sub> and AUC<sub>last</sub>. Considering the OGTT results, these changes in metformin concentration did not affect glucose concentration. In addition, there were no significant findings regarding safety profiles.</AbstractText><CopyrightInformation>&#xa9; 2025 Lee et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4800-4348</Identifier><AffiliationInfo><Affiliation>Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chae</LastName><ForeName>Sumin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Minji</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0001-3558-8516</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shim</LastName><ForeName>Wang-Seob</ForeName><Initials>WS</Initials><Identifier Source="ORCID">0000-0002-0903-1386</Identifier><AffiliationInfo><Affiliation>Kyung Hee Drug Analysis Center, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyung-Tae</ForeName><Initials>KT</Initials><Identifier Source="ORCID">0000-0002-3141-3727</Identifier><AffiliationInfo><Affiliation>Kyung Hee Drug Analysis Center, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yim</LastName><ForeName>Sung-Vin</ForeName><Initials>SV</Initials><Identifier Source="ORCID">0000-0003-4393-800X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Bo-Hyung</ForeName><Initials>BH</Initials><Identifier Source="ORCID">0000-0003-3233-2918</Identifier><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, Kyung Hee University Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Science and Technology, Graduate School, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>East-West Medical Research Institute, Kyung Hee University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000068397">Clinical Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Des Devel Ther</MedlineTA><NlmUniqueID>101475745</NlmUniqueID><ISSNLinking>1177-8881</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="Y">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005951" MajorTopicYN="N">Glucose Tolerance Test</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">drug-herb interaction</Keyword><Keyword MajorTopicYN="N">metformin</Keyword><Keyword MajorTopicYN="N">ojeok-san</Keyword><Keyword MajorTopicYN="N">pharmacodynamics</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword></KeywordList><CoiStatement>The authors report no conflicts of interest in this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>8</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40951699</ArticleId><ArticleId IdType="pmc">PMC12423445</ArticleId><ArticleId IdType="doi">10.2147/DDDT.S526915</ArticleId><ArticleId IdType="pii">526915</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. <i>Lancet</i>. 2017;389(10085):2239&#x2013;2251. doi: 10.1016/S0140-6736(17)30058-2
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)30058-2</ArticleId><ArticleId IdType="pubmed">28190580</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Classification of diabetes mellitus. Available from: https://apps.who.int/iris/handle/10665/325182. Accessed March
10, 2025.</Citation></Reference><Reference><Citation>Kosiborod M, Gomes MB, Nicolucci A, et al. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). <i>Cardiovasc Diabetol</i>. 2018;17(1):150. doi: 10.1186/s12933-018-0787-8
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-018-0787-8</ArticleId><ArticleId IdType="pmc">PMC6260731</ArticleId><ArticleId IdType="pubmed">30486889</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators GBDD. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021. <i>Lancet</i>. 2023;402(10397):203&#x2013;234. doi: 10.1016/S0140-6736(23)01301-6
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)01301-6</ArticleId><ArticleId IdType="pmc">PMC10364581</ArticleId><ArticleId IdType="pubmed">37356446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae JH, Han KD, Ko SH, et al. Diabetes fact sheet in Korea 2021. <i>Diabetes Metab J</i>. 2022;46(3):417&#x2013;426. doi: 10.4093/dmj.2022.0106
</Citation><ArticleIdList><ArticleId IdType="doi">10.4093/dmj.2022.0106</ArticleId><ArticleId IdType="pmc">PMC9171160</ArticleId><ArticleId IdType="pubmed">35656565</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. National diabetes statistics report website. Available from: https://www.cdc.gov/diabetes/php/data-research/index.html. Accessed March
10, 2025.</Citation></Reference><Reference><Citation>Solini A, Tric&#xf2; D. Clinical efficacy and cost-effectiveness of metformin in different patient populations: a narrative review of real-world evidence. <i>Diabetes Obes Metab</i>. 2024;26(3):20&#x2013;30. doi: 10.1111/dom.15729
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.15729</ArticleId><ArticleId IdType="pubmed">38939954</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu Y, Peng M, Tang X, et al. Protective effects of metformin in various cardiovascular diseases: clinical evidence and AMPK-dependent mechanisms. <i>J Cell Mol Med</i>. 2022;26(19):4886&#x2013;4903. doi: 10.1111/jcmm.17519
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.17519</ArticleId><ArticleId IdType="pmc">PMC9549498</ArticleId><ArticleId IdType="pubmed">36052760</ArticleId></ArticleIdList></Reference><Reference><Citation>Stage TB, Brosen K, Christensen MM. A comprehensive review of drug-drug interactions with metformin. <i>Clin Pharmacokinet</i>. 2015;54(8):811&#x2013;824. doi: 10.1007/s40262-015-0270-6
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-015-0270-6</ArticleId><ArticleId IdType="pubmed">25943187</ArticleId></ArticleIdList></Reference><Reference><Citation>Szymczak-Pajor I, Wenclewska S, &#x15a;liwi&#x144;ska A. Metabolic action of metformin. <i>Pharmaceuticals</i>. 2022;15(7):810. doi: 10.3390/ph15070810
</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15070810</ArticleId><ArticleId IdType="pmc">PMC9317619</ArticleId><ArticleId IdType="pubmed">35890109</ArticleId></ArticleIdList></Reference><Reference><Citation>Polianskyte-Prause Z, Tolvanen TA, Lindfors S, et al. Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. <i>FASEB J</i>. 2019;33(2):2858&#x2013;2869. doi: 10.1096/fj.201800529RR
</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201800529RR</ArticleId><ArticleId IdType="pmc">PMC6338644</ArticleId><ArticleId IdType="pubmed">30321069</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta RC, Chang D, Nammi S, Bensoussan A, Bilinski K, Roufogalis BD. Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications. <i>Diabetol Metab Syndr</i>. 2017;9(1):59. doi: 10.1186/s13098-017-0254-9
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13098-017-0254-9</ArticleId><ArticleId IdType="pmc">PMC5527439</ArticleId><ArticleId IdType="pubmed">28770011</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean National Health Insurance Service (KNHIS). Report on insurance claims for reimbursement from the National Health Insurance Service (NHIS). 2023. Available from: https://www.hira.or.kr/bbsDummy.do?pgmid=HIRAA020045010000&amp;brdScnBltNo=4&amp;brdBltNo=2405&amp;pageIndex=1&amp;pageIndex2=1. Accessed March
10, 2025.</Citation></Reference><Reference><Citation>Kim JH, Seo CS, Kim SS, Shin HK. Quality assessment of ojeok-san, a traditional herbal formula, using high-performance liquid chromatography combined with chemometric analysis. <i>J Anal Methods Chem</i>. 2015;2015:607252. doi: 10.1155/2015/607252
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/607252</ArticleId><ArticleId IdType="pmc">PMC4619932</ArticleId><ArticleId IdType="pubmed">26539304</ArticleId></ArticleIdList></Reference><Reference><Citation>Han TK, Proctor WR, Costales CL, Cai H, Everett RS, Thakker DR. Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers. <i>J Pharmacol Exp Ther</i>. 2015;352(3):519&#x2013;528. doi: 10.1124/jpet.114.220350
</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.114.220350</ArticleId><ArticleId IdType="pmc">PMC4352590</ArticleId><ArticleId IdType="pubmed">25563903</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng A, Gong C, Xu Y, et al. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis. <i>Front Public Health</i>. 2023;11:1183879. doi: 10.3389/fpubh.2023.1183879
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1183879</ArticleId><ArticleId IdType="pmc">PMC10400771</ArticleId><ArticleId IdType="pubmed">37546319</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Leask MP, Lee K, et al. The population-specific Thr44Met OCT3 coding variant affects metformin pharmacokinetics with subsequent effects on insulin sensitivity in C57Bl/6J mice. <i>Diabetologia</i>. 2025;68(3):537&#x2013;548. doi: 10.1007/s00125-024-06287-1
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-024-06287-1</ArticleId><ArticleId IdType="pmc">PMC11832584</ArticleId><ArticleId IdType="pubmed">39422716</ArticleId></ArticleIdList></Reference><Reference><Citation>Team RC. <i>A Language and Environment for Statistical Computing</i>. R Foundation for Statistical Computing; 2024.</Citation></Reference><Reference><Citation>Wickham H. <i>ggplot2: Elegant Graphics for Data Analysis</i>. 2nd ed. New York, NY: Springer-Verlag; 2016.</Citation></Reference><Reference><Citation>Nguyen JT, Tian DD, Tanna RS, et al. Assessing transporter-mediated natural product-drug interactions via in vitro-in vivo extrapolation: clinical evaluation with a probe cocktail. <i>Clin Pharmacol Ther</i>. 2021;109(5):1342&#x2013;1352. doi: 10.1002/cpt.2107
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2107</ArticleId><ArticleId IdType="pmc">PMC8058163</ArticleId><ArticleId IdType="pubmed">33174626</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. <i>Clin Pharmacokinet</i>. 2011;50(2):81&#x2013;98. doi: 10.2165/11534750-000000000-00000
</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11534750-000000000-00000</ArticleId><ArticleId IdType="pubmed">21241070</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H, Oh J, Yoon SH, Yu KS, Cho JY, Chung JY. A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: an open-label, parallel group, randomized clinical study. <i>PLoS One</i>. 2018;13(1):e0191258. doi: 10.1371/journal.pone.0191258
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0191258</ArticleId><ArticleId IdType="pmc">PMC5771593</ArticleId><ArticleId IdType="pubmed">29342199</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo H, Kim Y, Jang IJ, Yu KS, Lee S. Pharmacokinetic/pharmacodynamic interactions between evogliptin and glimepiride in healthy male subjects. <i>Drug Des Devel Ther</i>. 2020;14:5179&#x2013;5187. doi: 10.2147/DDDT.S275343</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S275343</ArticleId><ArticleId IdType="pmc">PMC7699451</ArticleId><ArticleId IdType="pubmed">33262578</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA, Fraser SF, Bird SR, Benson AC. Reproducibility of multiple repeated oral glucose tolerance tests. <i>Diabet Res Clin Pract</i>. 2011;94(3):e78&#x2013;82. doi: 10.1016/j.diabres.2011.08.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2011.08.025</ArticleId><ArticleId IdType="pubmed">21945562</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong L, Harmark L, van Puijenbroek E. Time course, outcome and management of adverse drug reactions associated with metformin from patient&#x2019;s perspective: a prospective, observational cohort study in the Netherlands. <i>Eur J Clin Pharmacol</i>. 2016;72(5):615&#x2013;622. doi: 10.1007/s00228-016-2019-z
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-016-2019-z</ArticleId><ArticleId IdType="pubmed">26864966</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. M12 Drug Interaction Studies: Guidance for Industry. 2024. Available from
https://www.fda.gov/media/161199/download. Accessed August
29, 2025.</Citation></Reference><Reference><Citation>Lee M-S, Jeong S-M, Oh S-H, et al. A retrospective study on the effect of the co-administration of ojeok-san and hypoglycemic agents on blood glucose levels in type 2 diabetes mellitus. <i>J Int Korean Med</i>. 2021;42(1):40&#x2013;52. doi: 10.22246/jikm.2021.42.1.40</Citation><ArticleIdList><ArticleId IdType="doi">10.22246/jikm.2021.42.1.40</ArticleId></ArticleIdList></Reference><Reference><Citation>Company B-MS. Labelling-package insert for GLUCOPHAGE (metformin hydrochloride) tablets. Bristol-Myers Squibb Company. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020357s034,021202s018lbl.pdf. Accessed May
29, 2025.</Citation></Reference><Reference><Citation>Sambol NC, Chiang J, O&#x2019;Conner M, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. <i>J Clin Pharmacol</i>. 1996;36(11):1012&#x2013;1021. doi: 10.1177/009127009603601105
</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/009127009603601105</ArticleId><ArticleId IdType="pubmed">8973990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuan IHS, Wilson LC, Leishman JC, et al. Metformin doses to ensure efficacy and safety in patients with reduced kidney function. <i>PLoS One</i>. 2021;16(2):e0246247. doi: 10.1371/journal.pone.0246247
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0246247</ArticleId><ArticleId IdType="pmc">PMC7891741</ArticleId><ArticleId IdType="pubmed">33600406</ArticleId></ArticleIdList></Reference><Reference><Citation>KDIGO. Clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2022;102(5s):S1&#x2013;s127. doi: 10.1016/j.kint.2022.06.008
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2022.06.008</ArticleId><ArticleId IdType="pubmed">36272764</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40839056</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2107-0180</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of drug metabolism and pharmacokinetics</Title><ISOAbbreviation>Eur J Drug Metab Pharmacokinet</ISOAbbreviation></Journal><ArticleTitle>Bioequivalence and Pharmacokinetic Evaluation of Two Metformin Hydrochloride Tablets Under Fasting and Fed Conditions in Healthy Chinese Volunteers.</ArticleTitle><Pagination><StartPage>431</StartPage><EndPage>440</EndPage><MedlinePgn>431-440</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13318-025-00961-4</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">With diabetes prevalence rising and original formulations unable to meet demand, establishing generic equivalence is crucial for treatment accessibility. This study evaluated the bioequivalence of generic metformin hydrochloride (0.25&#xa0;g) versus the reference drug in Chinese volunteers under fasting and fed conditions.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this randomized, open-label, two-period crossover trial, 26 healthy volunteers per group received single doses under fasting and fed conditions. Plasma concentrations were measured using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, pharmacokinetic metrics were calculated using the WinNonlin 6.3 software, and bioequivalence was evaluated using SAS 9.4.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Under fasting conditions, the geometric mean ratios (GMRs) between the test and reference groups were 103.12% (C<sub>max</sub>), 103.65% (AUC<sub>0-t</sub>), and 103.31% (AUC<sub>0-&#x221e;</sub>), with 90% CIs of 92.64-114.78%, 96.04-111.85%, and 96.00-111.17%, respectively. Fed conditions yielded GMRs of 93.98% (C<sub>max</sub>), 97.34% (AUC<sub>0-t</sub>), and 96.97% (AUC<sub>0-&#x221e;</sub>), with 90% CIs of 89.42-98.78%, 92.72-102.18%, and 92.40-101.78%, respectively. All these parameters met bioequivalence criteria (80-125%). Median T<sub>max</sub> was delayed under fed conditions (2.125 h vs. 4.000 h), with consistent food effects (reduced C<sub>max</sub> and AUC) and safety profiles between formulations.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results demonstrate that the generic metformin formulation is bioequivalent to the innovative product and well tolerated in Chinese healthy volunteers under both fasting and fed conditions.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Yuxing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Trials Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 ChangLin Road, XiQing District, Tianjin, 300193, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300193, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cai</LastName><ForeName>Qiuhan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Clinical Trials Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 ChangLin Road, XiQing District, Tianjin, 300193, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300193, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Meifang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Trials Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 ChangLin Road, XiQing District, Tianjin, 300193, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300193, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Shengxuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Trials Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 ChangLin Road, XiQing District, Tianjin, 300193, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300193, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Gaiying</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Trials Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 ChangLin Road, XiQing District, Tianjin, 300193, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300193, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Siyuan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Trials Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 ChangLin Road, XiQing District, Tianjin, 300193, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300193, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Chengliang</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-6200-0749</Identifier><AffiliationInfo><Affiliation>Clinical Trials Center, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 ChangLin Road, XiQing District, Tianjin, 300193, China. clitripro@sina.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, 300193, China. clitripro@sina.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Eur J Drug Metab Pharmacokinet</MedlineTA><NlmUniqueID>7608491</NlmUniqueID><ISSNLinking>0378-7966</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016568">Drugs, Generic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Population" UI="C000724312">Chinese people</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016568" MajorTopicYN="Y">Drugs, Generic</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005215" MajorTopicYN="Y">Fasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018565" MajorTopicYN="N">Food-Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declarations. Author Contributions: All authors made substantial contributions to the study conception, data acquisition, analysis, or interpretation. The initial manuscript draft was prepared by Yuxing Huang, with all coauthors contributing to critical revision of the content. All authors approved the final version for submission and assume full responsibility for the academic integrity of this work. Funding: This trial was sponsored by Tianjin Kangrui Pharmaceutical Co., Ltd. Data Availability: Data archiving is not mandated but data will be made available on reasonable request. Code Availability: Not applicable. Conflict of interest: Yuxing Huang, Qiuhan Cai, Mei fang Li, Shengxuan Guo, Gaiying Dong, Siyuan Hu and Chengliang Zhong are all employees of the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. All of the authors declare no conflicts of interest. Ethical Approval: This study protocol was approved by the Medical Ethics Committee at the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine on 23 January 2018 (registration number: TYLL2018Y002). Consent to Participate: All study participants provided written informed consent. Consent for Publication: Not applicable.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>30</Day><Hour>4</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>30</Day><Hour>4</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>21</Day><Hour>11</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40839056</ArticleId><ArticleId IdType="pmc">PMC12394267</ArticleId><ArticleId IdType="doi">10.1007/s13318-025-00961-4</ArticleId><ArticleId IdType="pii">10.1007/s13318-025-00961-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Luo YY, Zhu YZ, Chen J, et al. A decision support software to improve the standard care in Chinese type 2 diabetes. J Diabetes Res. 2019. 10.1155/2019/5491743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/5491743</ArticleId><ArticleId IdType="pmc">PMC6881560</ArticleId><ArticleId IdType="pubmed">31828162</ArticleId></ArticleIdList></Reference><Reference><Citation>Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157: 107843. 10.1016/j.diabres.2019.107843.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2019.107843</ArticleId><ArticleId IdType="pubmed">31518657</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311&#x2013;21. 10.1016/j.diabres.2011.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2011.10.029</ArticleId><ArticleId IdType="pubmed">22079683</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai QH, Wang ZD. Investigation of diabetes status in China. Guide China Med. 2011;9(13):206&#x2013;8. 10.15912/j.cnki.gocm.2011.13.136.</Citation><ArticleIdList><ArticleId IdType="doi">10.15912/j.cnki.gocm.2011.13.136</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang LM, Wen P, Zhao ZP, et al. Prevalence and treatment of diabetes in China, 2013&#x2013;2018. JAMA. 2021;326(24):2498&#x2013;506. 10.1001/jama.2021.22208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.22208</ArticleId><ArticleId IdType="pmc">PMC8715349</ArticleId><ArticleId IdType="pubmed">34962526</ArticleId></ArticleIdList></Reference><Reference><Citation>Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19):1926&#x2013;7. 10.1001/jama.2019.3805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.3805</ArticleId><ArticleId IdType="pmc">PMC7552083</ArticleId><ArticleId IdType="pubmed">31009043</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahami D, D&#x2019;Andrea E, Yin H, et al. Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. 2023;25(10):2980&#x2013;8. 10.1111/dom.15196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.15196</ArticleId><ArticleId IdType="pmc">PMC10527897</ArticleId><ArticleId IdType="pubmed">37395339</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2020. Diabetes Care 2020; 43(Suppl. 1): S98-S110. Diabetes Care. 2020; 43(8): 1979. 10.2337/dc20-ad08a.</Citation><ArticleIdList><ArticleId IdType="pubmed">31862752</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey CJ. Metformin: historical overview. Diabetologia. 2017;60(9):1566&#x2013;76. 10.1007/s00125-017-4318-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4318-z</ArticleId><ArticleId IdType="pubmed">28776081</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(9):541&#x2013;9. 10.1056/nejm199508313330902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199508313330902</ArticleId><ArticleId IdType="pubmed">7623902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58(2):265&#x2013;78. 10.1016/j.ejpb.2004.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpb.2004.03.001</ArticleId><ArticleId IdType="pubmed">15296954</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang XM, Wang GZ, He BB, et al. Bioequivalence and pharmacokinetic evaluation of two metformin hydrochloride tablets under fasting and fed conditions in healthy Chinese volunteers. Clin Pharmacol Drug Dev. 2020;9(8):910&#x2013;7. 10.1002/cpdd.849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.849</ArticleId><ArticleId IdType="pubmed">32936533</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun ML, Liu F, Yan P, et al. Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: a meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies. Heliyon. 2023;9(7): e17906. 10.1016/j.heliyon.2023.e17906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e17906</ArticleId><ArticleId IdType="pmc">PMC10344758</ArticleId><ArticleId IdType="pubmed">37455965</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association, A. World Medical Association declaration of Helsinki ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191&#x2013;4. 10.1001/jama.2013.281053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Switula D. Principles of good clinical practice (GCP) in clinical research. Sci Eng Ethics. 2000;6(1):71&#x2013;7. 10.1007/s11948-000-0025-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11948-000-0025-z</ArticleId><ArticleId IdType="pubmed">11273440</ArticleId></ArticleIdList></Reference><Reference><Citation>CFDA. Technical Guidelines for Clinical Pharmacokinetic Studies of Chemical Drugs, 2016. www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20050318010101201.html. Accessed 18 Mar 2005.</Citation></Reference><Reference><Citation>Chinese Pharmacopoeia Commission. Guidelines for bioanalytical method validation. In: Pharmacopoeia of the People&#x2019;s Republic of China. 2015ed. Beijing, China Medical Science Press; 2015. p363&#x2013;368, Accessed 5 jun 2015</Citation></Reference><Reference><Citation>CFDA. Drug Registration Management Measures, 2020. www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/bmgzh/20200330180501220.html. Accessed 22 Jan 2020.</Citation></Reference><Reference><Citation>CFDA. Technical Guidelines for Human Bioequivalence Studies of Chemical Generic Drugs Using Pharmacokinetic Parameters as Endpoint Evaluation Indicators, 2016. www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20160318210001633.html.</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. (2010).&#xa0;Bioequivalence recommendations for specific products. U.S. Department of Health and Human Services. 2016, www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/. Accessed Jun 2010.</Citation></Reference><Reference><Citation>CFDA. Technical Guidelines for Bioequivalence Studies in Generic Drug Quality Consistency Evaluation, 2015. www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20151030120001643.html. Accessed 30 Oct 2015.</Citation></Reference><Reference><Citation>Yang WY, Guan YF, Shentu Y, et al. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes. 2012;4(3):227&#x2013;37. 10.1111/j.1753-0407.2012.00213.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1753-0407.2012.00213.x</ArticleId><ArticleId IdType="pubmed">22672586</ArticleId></ArticleIdList></Reference><Reference><Citation>Suna M-L, Liu F, Yan P, et al. Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: a meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies. Heliyon. 2023;9(7):e17906. 10.1016/j.heliyon.2023.e17906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e17906</ArticleId><ArticleId IdType="pmc">PMC10344758</ArticleId><ArticleId IdType="pubmed">37455965</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">21241070</ArticleId></ArticleIdList></Reference><Reference><Citation>Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch. 2004;447(5):666&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12883891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Duan H, Hebert MF, et al. Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands. J Biol Chem. 2014;289(39):27055&#x2013;64. 10.1074/jbc.M114.570564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.570564</ArticleId><ArticleId IdType="pmc">PMC4175343</ArticleId><ArticleId IdType="pubmed">25107910</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem. 2004;279(48):50042&#x2013;9. 10.1074/jbc.M407913200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407913200</ArticleId><ArticleId IdType="pubmed">15448143</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma mem brane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007;35(10):1956&#x2013;62. 10.1124/dmd.107.015495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.107.015495</ArticleId><ArticleId IdType="pmc">PMC2672958</ArticleId><ArticleId IdType="pubmed">17600084</ArticleId></ArticleIdList></Reference><Reference><Citation>McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426&#x2013;35. 10.1007/s00125-015-3844-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-015-3844-9</ArticleId><ArticleId IdType="pmc">PMC4742508</ArticleId><ArticleId IdType="pubmed">26780750</ArticleId></ArticleIdList></Reference><Reference><Citation>Marathe PH, Wen Y, Norton J, et al. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol. 2015;50(4):325&#x2013;32. 10.1046/j.1365-2125.2000.00264.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2125.2000.00264.x</ArticleId><ArticleId IdType="pmc">PMC2015004</ArticleId><ArticleId IdType="pubmed">11012555</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>